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ABSTRACT  
   
Patients with Alzheimer’s disease (AD) exhibit a significantly higher incidence of 
unprovoked seizures compared to age-matched non-AD controls, and animal 
models of AD (i.e., transgenic human amyloid precursor protein, hAPP mice) 
display neural hyper-excitation and epileptic seizures. Hyperexcitation is 
particularly important because it contributes to the high incidence of epilepsy in 
AD patients as well as AD-related synaptic deficits and neurodegeneration. Given 
that there is significant amyloid-β (Aβ) accumulation and deposition in AD brain, 
Aβ exposure ultimately may be responsible for neural hyper-excitation in both 
AD patients and animal models. Emerging evidence indicates that α7 nicotinic 
acetylcholine receptors (α7-nAChR) are involved in AD pathology, because 
synaptic impairment and learning and memory deficits in a hAPPα7-/- mouse 
model are decreased by nAChR α7 subunit gene deletion. Given that Aβ potently 
modulates α7-nAChR function, that α7-nAChR expression is significantly 
enhanced in both AD patients and animal models, and that α7-nAChR play an 
important role in regulating neuronal excitability, it is reasonable that α7-nAChRs 
may contribute to Aβ-induced neural hyperexcitation. We hypothesize that 
increased α7-nAChR expression and function as a consequence of Aβ exposure is 
important in Aβ-induced neural hyperexcitation. In this project, we found that 
exposure of Aβ aggregates at a nanomolar range induces neuronal hyperexcitation 
and toxicity via an upregulation of α7-nAChR in cultured hippocampus pyramidal 
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neurons. Aβ up-regulates α7-nAChRs function and expression through a post 
translational mechanism. α7-nAChR up-regulation occurs prior to Aβ-induced 
neuronal hyperexcitation and toxicity. Moreover, inhibition of α7-nAChR or 
deletion of α7-nAChR prevented Aβ induced neuronal hyperexcitation and 
toxicity, which suggests that α7-nAChRs are required for Aβ induced neuronal 
hyperexcitation and toxicity. These results reveal a profound role for α7-nAChR in 
mediating Aβ-induced neuronal hyperexcitation and toxicity and predict that Aβ-
induced up-regulation of α7-nAChR could be an early and critical event in AD 
etiopathogenesis. Drugs targeting α7-nAChR or seizure activity could be viable 
therapies for AD treatment.  
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Chapter 1 
OVERVIEW OF nAChR AND Aβ-INDUCED NEURONAL 
HYPEREXCITATION 
1.1 Neuronal nAChR 
 
1.1.1 Structure and distribution of nAChR in the central nervous system 
(CNS) 
nAChR are prototypical members of the ligand-gated ion channel superfamily of 
neurotransmitter receptors. nAChR represent both classic and contemporary 
models for the establishment of concepts pertaining to mechanisms of drug action, 
synaptic transmission and structural/functional diversity of transmembrane 
signaling molecules (Lindstrom et al., 1996; Lukas, 2006). nAChR are found 
throughout the nervous system (e.g. in autonomic and sensory ganglia and the 
central nervous system), exist as multiple, diverse subtypes, and are pentamers 
composed of unique combinations from a family of at least 17 (α1–α10, β1–β4, γ, 
δ and ε) similar, but genetically-distinct, subunits. Each subunit gene has a unique 
promoter, even though some genes are clustered, suggesting a means for cell-
specific expression. There are also unique protein sequence elements within each 
subunit, especially in the large, cytoplasmic loop, suggesting a differential post-
translational control of subunit trafficking. Most of these nAChR subtypes appear 
to exist as heteropentamers containing 2 or more different kinds of subunits. For 
example, heterologous expression studies suggest that α2, α3, α4 or α6 subunits 
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can combine in a binary fashion with β2 or β4 subunits to form ligand-binding 
and/or functional nAChR (e.g. α4β2-nAChR). β3 and α5 subunits are ‘wild-cards’. 
They are not able to form functional nAChR on their own or with any other single 
type of subunit, but they are capable of integrating into complexes with 2 or more 
other subunit types to form distinctive trinary or ternary (that also contain more 
than one of the α2-α4, α6, β2 or β4 subunits found in binary complexes) 
complexes such as the α4β2α5-nAChR or the α3β2β4α5-nAChR (which is 
naturally expressed). In contrast, phylogenetically-ancient nAChR α7 subunits are 
able to form functional homopentamers, which constitute the simplest possible 
prototype for a ligand-gated ion channel. nAChR containing α7 subunits (α7-
nAChR) or α4 and β2 subunits (α4β2*-nAChR) are the most abundant 
curaremimetic neurotoxin-binding and high affinity nicotine-binding nAChR in 
the brain. However, other less-abundant nAChR (e.g. α3*-nAChR or α6*-nAChR) 
exist and may also play important roles in brain physiological regulation. 
 
1.1.2 Function of neuronal nAChR 
nAChR function in the vertebrate muscle has been comprehensively characterized, 
and studies of functional nAChR in autonomic ganglia are rather advanced 
(Jensen et al., 2005; Lukas, 2006). In regards to nAChR found centrally, there has 
been heavy reliance on heterologous expression studies, principally using oocytes 
as hosts, but the use of transfected mammalian cells has also assisted in defining the 
realm of possibilities for nAChR subunit compositions that are capable of forming 
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functional, ligand-gated ion channels. Significant insights have been gained about 
functional nAChR in the brain from a substantial body of evidence derived using 
electrophysiological recordings, neurotransmitter release analyses, isotopic ion 
flux studies and internal calcium ion imaging. Studies using transgenic mice have 
helped to identify subunits that constitute some native, functional nAChR subtypes 
(Picciotto et al., 1998; Klink et al., 2001; Marubio et al., 2003; Champtiaux and 
Changeux, 2004; Salminen et al., 2004). Taken collectively, recent findings have 
indicated that nAChR in the brain play roles not only in the mediation of classic, 
excitatory, cholinergic neurotransmission at selected loci, but also and perhaps 
more globally, in the modulation of neurotransmission by other chemical 
messengers, including glutamate, γ-aminobutyric acid (GABA), the monoamines 
dopamine, norepinephrine, serotonin and acetylcholine (ACh) itself (McGehee 
and Role, 1995; Alkondon et al., 1997; McGehee, 1999; Jensen et al., 2005). This 
means that some nAChR subtypes have post-synaptic (or peri-synaptic) 
somatodendritic localizations, whereas others have pre-synaptic dispositions. 
Moreover, some nAChR have been implicated in processes such as the structuring 
and maintenance of neurites and synapses (Freeman, 1977; Chan and Quik, 1993; 
Pugh and Berg, 1994; Renshaw, 1994) and even in the modulation of neuronal 
viability and/or death (Renshaw, 1994; Hory-Lee and Frank, 1995; Renshaw and 
Dyson, 1995; Treinin and Chalfie, 1995). Therefore, nAChR play complex and 
interesting roles in the modulation of chemical milieu in the brain, for the 
completion of neuronal circuits, and perhaps for the formation and maintenance of 
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synapses. However, more work is required to define functional nAChR in the 
central nervous system and to determine their cellular distributions. Additional 
studies are also required to determine whether distinctive subunit combinations 
dictate whether a given nAChR subtype will be positioned pre- or post-synaptically 
or whether the same nAChR subtype can have either disposition dependent on 
cellular environment.  
 
As examples, functional nAChR in the hippocampus, in the neurons of the 
mesocorticolimbic dopamine (DA) system, including the ventral tegmental area 
(VTA) and substantia nigra pars compacta (SNc), or in forebrain cholinergic 
neurons, have received attention (Wonnacott et al., 1990; Alkondon and 
Albuquerque, 1993; Alkondon et al., 1996; Dani et al., 2000; Mike et al., 2000; 
Dani and De Biasi, 2001). Some of these functional analyses utilized 
electrophysiological recordings from brain slices as well as primary cultured 
hippocampal neurons. Recent exceptions include studies demonstrating the 
expression in the VTA of functionally distinct nAChR, including homomeric α7-
nAChR, which are expressed on less than one-half of VTA DAergic neurons, and 
a variety of non-α7-nAChR, provisionally identified as α4α6α5(β2)2-, α4α5(β2)2-, 
α6β2-, and α4β2-nAChR (Klink et al., 2001; Champtiaux et al., 2003; Wu et al., 
2005). One complication is that the function of some of these putative subtypes 
has not been convincingly demonstrated, leaving open the possibility that the 
immunoisolates are not functional nAChR found on the cell membrane. 
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Interestingly, GABAergic neurons located in the VTA are likely to express 
relatively simple nAChR subtypes, mainly the α4β2-nAChR, since less than 25% 
of GABAergic neurons express α3, α5, α6 and β4 subunits (Klink et al., 2001). 
Recently, several research groups have focused their attention on nAChR function 
in forebrain neurons (Klink et al., 2001; Thinschmidt et al., 2005b, a) and have 
found that these nAChR not only participate in forebrain neuronal function, but 
are also modulated by Aβ (Fu and Jhamandas, 2003). The diversity in the 
expression of nAChR subtypes and subunits on different types of neurons located 
in different brain regions might be the rule more than the exception for other brain 
regions, but more work is needed before definitive conclusions can be drawn. 
 
1.2 Aβ and neuronal hyperexcitation 
1.2.1 Aβ and senile plaques 
Clinical evidence indicates that amyloid or senile plaques are responsible for the 
pathogenesis of Alzheimer’s disease (AD) (Auld et al., 2002). These plaques are 
mainly composed of the Aβ peptide, which is obtained from an amyloid precursor 
protein (APP) by proteolytic cleavage and exists in 2 predominant forms: the 40-
residue Aβ1–40 and the 42-residue Aβ1–42. Aβ1–40 represents the majority of the Aβ 
population in normal individuals (Mori et al., 1992; Caughey and Lansbury, 2003) 
and Aβ1–42, which exhibits trophic and toxic effects on neurons (Zamani and Allen, 
2001; Auld et al., 2002), appears to induce the pathogenesis of AD. 
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1.2.2 Aβ accumulation in AD: in vivo and in vitro studies 
A large body of evidence indicates that the accumulation of large intracellular and 
extracellular aggregates is a histopathological hallmark for the terminal diagnosis 
of AD. However, it has long been known that the extent of amyloid accumulation 
does not correlate well with AD pathogenesis (Terry, 1996) and that a significant 
number of individuals who have not suffered dementia have also shown notable 
amounts of amyloid plaques. Among in vivo transgenic animals and in vitro cell 
culture models, pathological changes are frequently observed prior to the onset of 
amyloid accumulation. These seemingly conflicting lines of evidence can be 
reconciled by postulating that soluble Aβ, rather than the mature fibrils, represents 
the primary toxic species in amyloid-associated degenerative disease (Terry et al., 
1991; Klein, 2002). In AD patients, soluble Aβ correlates better with cognitive 
decline and loss of synaptic proteins than insoluble, fibril deposits (Lue et al., 
1999; McLean et al., 1999). In amyloid precursor protein transgenic mouse 
models, neurological deficits precede the deposition of significant amounts of Aβ, 
suggesting that the pathophysiology of AD occurs prior to amyloid fibril 
deposition (Hsia et al., 1999; Westerman et al., 2002). 
On the other hand, evidence has also shown heterogeneity in extracellular 
amyloid in plaques (D'Andrea et al., 2004). Contrary to the popularized dogma 
that all amyloid plaques arise from extracellular deposition, the different forms 
and magnitudes of amyloid plaques could be the result of multiple 
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mechanisms of formation. For example, it has been proposed that diffuse and 
dense-core (senile) amyloid plaques differ with respect to glial activity, with the 
latter primarily being associated with highly reactive microglia (McGeer et al., 
1994). The popular story of extracellular amyloid aggregation which fails to 
account for the observed heterogeneity in plaques and detected intracellular Aβ 
together attracts more attention to the mechanisms and intracellular aspects of Aβ 
plaque formation. 
 
1.2.3 AD and epilepsy 
Patients with AD exhibit a significantly higher incidence of unprovoked seizures 
compared to the age-matched non-AD controls, and animal models of AD (i.e., 
transgenic human amyloid precursor protein, hAPP mice) display neural hyper-
excitation and epileptic seizures (Hesdorffer et al., 1996; Mendez and Lim, 2003; 
Amatniek et al., 2006; Lozsadi and Larner, 2006; Palop et al., 2007; Busche et al., 
2008; Hommet et al., 2008; Westmark et al., 2008; Larner, 2009; Minkeviciene et 
al., 2009; Palop and Mucke, 2009a). Hauser et al. reported 10 times more 
incidence of seizures in AD population than a reference population (Hauser et al., 
1986). Some other studies suggested even higher proportion of affected patients in 
AD population than that in age matched, non-AD controls (Hesdorffer et al., 1996; 
Mendez and Lim, 2003; Amatniek et al., 2006; Lozsadi and Larner, 2006; Hommet 
et al., 2008). The risk of seizure activity is especially high at an early stage of 
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dementia onset. It has been reported that there is an 87-fold enhancement of seizure 
incidence in the AD patients with early stages of syndromes compared to an age-
matched reference populations (Mendez, 1994; Rabinowicz et al., 2000; Amatniek 
et al., 2006). Rabinowics et al. (Rabinowicz et al., 2000) reported that epileptiform 
discharges were associated with transient episodes of amnestic wandering and 
disorientation in AD. Interestingly, the relationship between epilepsy and AD is 
even tighter in autosomal dominant early-onset in AD linked to mutations in 
presenilin-1, in presenilin-2, and/or APP (Edwards-Lee et al., 2000; Marcon et al., 
2004; Snider et al., 2005). Together, these data suggest that epilepsy is an important 
phenotype of AD (Westmark et al., 2008), and Aβ-induced aberrant neural 
hyperexcitation and seizures that cause synaptic impairment and cognitive deficits 
may be an important mechanism for AD pathogenesis (Leonard and McNamara, 
2007). However, the mechanisms of epileptogenesis in AD are still unclear, and this 
gap in knowledge has limited our understanding of AD pathology and AD 
treatment. 
 
1.2.4 Aβ-induced neuronal hyperexcitation 
Emerging lines of evidence indicate that high-levels of Aβ induce neuronal or 
neurocircuit hyperexcitation. For example, chronic exposure to high levels of Aβ 
sensitizes some neuronal networks to hyperexcitation (Del Vecchio et al., 2004). 
In animals that over-express Aβ, the high-levels of Aβ peptide cause epileptiform 
activity within the entorhinal-hippocampal circuitry (Palop et al., 2007). 
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Westmark et al. (Westmark et al., 2008) compared seizure threshold (test response 
to pentylenetetrazol, PTZ) between AD model animals (Tg2576) and wild-type 
mice, and found a reduction of seizure threshold in AD model animals. By 
studying the mechanisms of neuronal hyperexcitation in AD model animals, 
Busche et al. (Busche et al., 2008) found that impaired synaptic inhibition, rather 
than Ca2+ release from intracellular stores, or intrinsic firing underlie neuronal 
hyperactivity. These lines of evidence suggest that Aβ induces neuronal 
hyperexcitation. Elucidation of the selective targets and underlying mechanisms 
in Aβ- induced neuronal hyperexcitation will provide important insights into the 
pathogenesis of AD and also could open new therapeutic avenues. 
 
1.2.5 Aβ is neurotoxic 
The addition of pre-aggregated Aβ to cell cultures causes a rapid and large 
increase in intracellular Ca2+, whereas equivalent amounts of soluble monomer 
and fibrils have no detectable effects (Salminen et al., 2004; Tapper et al., 2004). 
Moreover, Aβ specifically permeabilizes cell membranes. The Ca2+ influx is not 
blocked by cobalt, indicating that the effect is not due to the activation of existing 
Ca2+ channels. Aβ also causes leakage of the membrane impermeant dye calcein 
from cells, indicating that a variety of molecules diffuse across the membrane 
following Aβ treatment. This conclusion is in agreement with previous studies 
that reported that Aβ induced the release of dye from phospholipid vesicles 
(Janson et al., 1999; Anguiano et al., 2002). It has also been observed in cell 
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cultures that Aβ treatment results in an increase in cytosolic Ca2+ in Ca2+-free 
medium. This increase can be largely eliminated by pre-treatment with 
thapsigargin, which depletes endoplasmic reticulum calcium stores (Mina EW, 
2004), suggesting that external application of Aβ leads to the liberation of Ca2+ 
from intracellular stores. This is consistent with reports that Aβ may penetrate 
into cells and disrupt intracellular membranes, causing leakage of sequestered 
Ca2+, but it could also be the consequence of altered intracellular signaling 
(Rothem et al., 2004). It has been reported that acute application of pre-
aggregated Aβ can hyperpolarize the hippocampal neuron resting membrane 
potential and inhibited action potential firings (Sun et al., 2003).  Under in vivo 
conditions, the chronic leakage of ions across the plasma membrane may be 
sufficient to disrupt normal neuronal function and serve as a source of chronic 
stress that may impair the maintenance of normal membrane potential. In addition 
to Ca2+ channel activity, Aβ also seems to activate K+ channels. The mechanism 
by which Aβ increases K+ current, which results in ensuing neurotoxicity, is 
unknown, but oxidative stress may be a factor (Pike et al., 1996; Colom et al., 
1998). 
In summary, studies using both in vivo and in vitro preparations indicate that Aβ 
is neurotoxic and plays a direct role in the pathogenesis of AD. 
 
1.3 Aβ modulates nAChR 
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1.3.1 Neuronal nAChR changes in AD 
The roles of cholinergic signaling and nAChR in cognitive function and 
development are well documented (Levin, 1992; Granon et al., 1995). Impaired 
cognition found in AD patients is believed to be correlated with forebrain 
cholinergic neural degeneration (Sugaya et al., 1990; Rossner et al., 1998), and 
the cholinergic system has been postulated to be the primary target in AD (Davies 
and Maloney, 1976; Perry et al., 1977). Molecular and neurochemical evidence 
has indicated that changes in nAChR subtypes occur in the brain of AD patients. 
Evidence also indicates that a consistent, significant loss of α4-containing nAChR 
occurs in a number of neocortical areas and in the hippocampus of patients with 
AD (Court et al., 2001; Nordberg, 2001). Cortical α4*-nAChR deficits are 
significantly correlated with cognitive impairment in AD patients (Nordberg et al., 
1995; Nordberg et al., 1997). For example, by measuring the binding of specific 
radiolabeled ligands, such as [3H] epibatidine and [125I] α-bungarotoxin to reflect 
receptor numbers, a reduction in α4- and α7-nAChR binding sites was found to be 
associated with AD. On the other hand, the numbers of binding sites reflective of 
the α4 subtype were significantly elevated in individuals who were habitual 
smokers (Aubert et al., 1992; Hellstrom-Lindahl et al., 1999; Martin-Ruiz et al., 
1999). However, mRNA levels of different nAChR subtypes, measured either by 
in situ hybridization or quantitative RT-PCR, were not different when controls 
and patients with AD were compared (Terzano et al., 1998; Mousavi et al., 2003). 
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1.3.2 Conflicting results 
Recent evidence has indicated that nAChR serve as central targets for Aβ-induced 
neurotoxic manifestations such as cholinergic hypofunction and cognitive 
impairment. However, the action of Aβ on nAChR is not straightforward and 
there are several discrepancies among different research groups. Some 
experiments using in vitro preparations suggest that Aβ acts as a nAChR agonist. 
For example, Aβ1–42 has been shown to activate α7-nAChR expressed in Xenopus 
oocytes (Dineley et al., 2002a) and native non-α7-nAChR in acutely dissociated 
rat basal forebrain neurons (Fu and Jhamandas, 2003). Using isolated pre-synaptic 
nerve endings from a rat hippocampus and neocortex combined with confocal 
Ca2+ imaging, Aβ1–42 was found to directly evoke a sustained increase in pre-
synaptic Ca2+ levels via nAChR (Dougherty et al., 2003). This action seemed to 
involve both α7- and non-α7-nAChR. On the other hand, other groups, including 
our laboratory, have shown evidence that Aβ acts on nAChR as an antagonist. 
Aβ1–42 was shown to block native α7-containing nAChR in cultured rat 
hippocampal neurons (Liu et al., 2001), human α7-nAChR in Xenopus oocytes 
(Grassi et al., 2003), rat α4β2-nAChR in Xenopus oocytes(Tozaki et al., 2002), 
human α4β2-nAChs in human SH-EP1 cells (Wu et al., 2004a), mouse muscle 
nAChR in human kidney BOSC 23 cells (Grassi et al., 2003), Torpedo nAChR in 
Xenopus oocytes (Tozaki et al., 2002) and non-α7-nAChR, including α2β2-, 
α4β2- and α4α5β2-nAChR in Xenopus oocytes(Lamb et al., 2005). Recently, a 
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specially designed peptide that binds to Aβ with high affinity has been reported, 
and interestingly, this peptide virtually abolishes Aβ-induced nAChR inhibition 
(Magdesian et al., 2005). Therefore, although there are some inconsistencies 
about the effects of Aβ, which may be explained by the different preparations of 
Aβ used on different sub-types of nAChR by different groups, all of the above-
mentioned studies suggest that there are some interactions between Aβ and 
nAChR. 
 
1.3.3 Aβ modulates nAChR: possible mechanisms  
There are 2 main features of AD: Aβ protein deposition and neuronal deficits(Liu 
and Wu, 2006). Aβ is a 39- to 43-amino acid transmembrane fragment of a large 
precursor molecule and is found in diffuse and focal deposits throughout the brain 
in AD patients. It has been shown that the Aβ protein is a major constituent of 
senile plaque, a neuropathological hallmark of AD and a neurotoxin in various in 
vivo and in vitro studies. Although the mechanisms by which Aβ causes cholinergic 
neuronal degeneration are not fully understood, a few hypotheses have been 
proposed based on current, growing evidence: (1) neuronal death, either by 
apoptosis or necrosis, primarily occurs in the cholinergic system; (2) insertion of 
Aβ proteins into the cell membrane destabilizes the membrane and affects its 
fluidity (Muller et al., 1995; Avdulov et al., 1997; Kanfer et al., 1999); (3) Aβ 
affects intracellular Ca2+ homeostasis through either the production of cation 
ionophores or activation of ligand- and/or voltage-gated channels (Arispe et al., 
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1994; Sanderson et al., 1997); and (4) Aβ affects nAChR function probably 
through oxidative processes (Murray et al., 2005; Tabner et al., 2005). Until now, 
the precise mechanisms by which Aβ selectively induces degeneration of forebrain 
cholinergic neurons in AD patients have been unclear. 
 
Among nAChR, the α7 subtype may play the most important role in mediating the 
toxicity of Aβ. It has been reported that Aβ1–42 binds to α7-nAChR with a higher 
affinity compared to Aβ1–40 (Wang et al., 2000b). Therefore, it has been suggested 
that chronic stimulation of α7-nAChR by Aβ, mainly by Aβ1–42 (Dineley et al., 
2002a) elevates, at least in part, intracellular Ca2+ levels. It is also involved in the 
chronic activation of the extracellular signal-regulated kinase (ERK2) isoform of 
the ERK mitogen-activated protein kinase (MAPK) cascade which leads to the 
downregulation of MAPK (Dineley et al., 2001). The ERK2–MAPK signaling 
pathway plays a critical role in memory formation (Tapper et al., 2004), and its 
derangement could in part explain the memory impairment observed in patients 
with AD. Moreover, it has been proposed that downregulation of ERK2–MAPK 
may be the initial step for a positive-feedback loop that results in Aβ 
accumulation (Mills et al., 1997; Dineley et al., 2001). There is also another 
explanation implicating the α7-nAChR (Nagele et al., 2002). Using in vitro 
preparations, the binding interaction between Aβ1–42, but not Aβ1–40, and α7-
nAChR facilitates internalization and intracellular accumulation of Aβ1–42 (Nagele 
et al., 2002). Immunohistochemistry and digital imaging studies have revealed 
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that neurons in the brain of AD patients which contain substantial intracellular 
accumulation of Aβ1–42 invariably express relatively high levels of α7-nAChR 
(Nagele et al., 2002). Furthermore, these studies prove the high co-localization of 
α7-nAChR and Aβ1–42 within neurons of AD brains. Michael et al introduced a 
new hypothesis referring to the co-localization of α7-nAChR and Aβ1–42. They 
suggested that amyloid plaques may derive from the lysis of forebrain neurons 
that are overburdened with intracellular accumulation of the α7-nAChR/Aβ1–42 
complex, which challenged the prevailing amyloid accumulation story (Nagele et 
al., 2002). This result provides a reasonable explanation for Aβ1–42 causing a 
reduction in the cell surface-associated α7-nAChR by a relocation of this receptor 
to intracellular Aβ1–42-positive deposits. This reduction results in the intracellular 
derangement of calcium cascade, which in turn leads to selective degeneration of 
cholinergic and cholinoceptive neurons in AD brains. 
 
Another consequence of the interaction between Aβ and α7-nAChR would be a 
derangement of the GABA system, which plays a role in long-term potentiation 
and learning (Jurgensen and Ferreira, 2010). α7-nAChR, located on GABAergic 
interneurons, modulates GABA release, and chronic stimulation of α7-nAChR 
would modify GABAergic signaling. Taking these results into consideration, 
compounds that are able to block the effects of Aβ on α7-nAChR function may 
possibly be used as therapeutic agents for AD. Moreover, the mechanisms of Aβ-
induced damage implicating nAChR have also been proposed to be involved in 
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the glutamatergic system (Chin et al., 2007). By inhibiting glutamate re-uptake by 
astrocytes, Aβ would promote excessive glutamate stimulation. Glutamate 
induces an increase in intracellular Ca2+ levels via activation of n-Methyl-D-
Aspartate (NMDA) receptors. This influx of Ca2+ activates nitric oxide (NO) 
synthase and leads to the production of toxic oxygen radicals and cell death 
(Freeman, 1977). It has also been reported that α7-nAChR stimulation would 
promote anti-apoptotic protein synthesis via elevation of intracellular Ca2+ levels 
and activation of phosphatidylinositol 3-kinase and Akt kinase (Kihara, 1998). 
These results suggest that α7-nAChR stimulation could be used as a 
neuroprotective therapy, which could provide the most benefit to patients with 
AD if the disease is diagnosed in the early stages of development. The above-
mentioned different mechanisms suggest that the consequences of α7-nAChR 
activation, desensitization or inactivation by Aβ1–42 or nAChR agonists, such as 
nicotine, on AD development are complex or even exhibit opposite effects, 
suggesting that Aβ modulation of nAChR function is indeed complicated. 
 
A significant decrease in the number of radioligand binding sites corresponding to 
nAChR, especially α4-containing nAChR, is one of the earliest events in the 
pathogenesis of AD (Burghaus et al., 2000), even preceding cholinergic neuronal 
degeneration. Further support for the cholinergic hypothesis of AD comes from 
observations that nicotine improves cognitive function in AD patients (Levin and 
Rezvani, 2002). Accumulating data also indicates that Aβ1–42 can block non-α7-
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nAChR in various neurons or cell lines (Muller et al., 1995; Avdulov et al., 1997). 
 
It has been reported that Aβ can directly modulate α4β2-nAChR function (Muller 
et al., 1995; Avdulov et al., 1997), which is the most abundant non-α7-nAChR 
subtype in the brain of vertebrates (Warpman and Nordberg, 1995; Nordberg, 
2001; Rezvani and Levin, 2001). Our data have shown that Aβ1–42, at a pathology-
relevant concentration (1 nM), can inhibit human α4β2-nAChR (hα4β2-nAChR) 
heterologously expressed in human SH-EP1 cells. Aβ1–42-mediated inhibition of 
hα4β2-nAChR function is non-competitive, voltage-independent and use-
independent. This downregulation of hα4β2-nAChR function by Aβ1–42 has been 
confirmed to not to be mediated by nAChR internalization (Wu et al., 2004b). In 
addition, we have demonstrated that there is no competition between Aβ1–42, at 
picomolar to micromolar concentrations, and nAChR agonists based on 
radioligand binding sites using heterologously expressed hα4β2- or hα7-nAChR. 
Therefore, our findings indicate that Aβ1–42 is likely to act as a non-competitive 
antagonist of hα4β2-nAChR (Wu et al., 2004b). 
 
In Xenopus oocytes expressing various non-α7-nAChR, including α4β2-nAChR, 
Aβ1–42 can reversibly block membrane currents induced by carbachol. More 
interestingly, altering the α4:β2 RNA ratio of α4β2-nAChR alters the sensitivity 
of nAChR to Aβ1–42. In other words, increasing the relative amount of the α4 
subunit significantly decreases the sensitivity of α4β2 channels to Aβ1–42, which 
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suggests that the relative block by Aβ1–42 is affected by the stoichiometry of α4β2 
channels (Lamb et al., 2005). Numerous studies have revealed that Aβ1–42 
regulates the function of non-α7-nAChR. However, links between losses in 
nAChR, cholinergic neuronal degeneration and the effects of Aβ have been 
elusive. 
 
Histological studies showing co-expression of nAChR α7 and β2 subunits in most 
forebrain cholinergic neurons (Azam et al., 2003), and heterologous expression 
work indicating that nAChR α7 and β2 subunits can come together to form 
heteromeric functional channels (Khiroug et al., 2002), suggest that although most 
α7-nAChR are formed as homomeric pentamers, others may exist as heteromers, 
including a possible α7β2-nAChR subtype. However, the expression of functional 
α7β2-nAChR in forebrain cholinergic neurons has not been demonstrated and 
their sensitivity to Aβ has not been determined. 
 
The predominant clinical syndrome associated with AD is a deficiency in both 
learning and memory capabilities. These deficits are thought to be due to selective 
forebrain cholinergic neuronal degeneration. Although this selective cholinergic 
neurodegeneration is largely unclear, several hypotheses have been postulated, 
including Aβ-induced toxicity, impairment of neuronal trophic support, disorders 
in glucose metabolism or other processes (Dolezal and Kasparova, 2003). The 
accumulation and aggregation of the Aβ protein in diffuse neuritic plaques is a 
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key pathological hallmark of AD. Aβ accumulation is thought to contribute to 
cholinergic neuronal degeneration, in turn causing learning and memory deficits 
(Selkoe, 1999). Evidence indicates that Aβ harms central neurons by affecting 
cellular Ca2+ homeostasis, neurotransmission, neuronal signaling and receptor/ion 
channel functions (Fraser et al., 1997). However, most of the relevant experiments 
have been done using Aβ at concentrations ranging between 100 nmol/L and 10 
μmol/L, which are much higher than Aβ concentrations (<5 nmol/L) found in the 
brain of patients with AD (Kuo et al., 2000; Mehta et al., 2000). Moreover, the 
effects of Aβ have been examined in a variety of cell types that may not be 
appropriate models to characterize the selective effects of Aβ on native forebrain 
cholinergic neurons. Figure 1 summarizes the roles of neuronal nAChR in 
mediating Aβ-induced neuronal degeneration. 
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Figure 1 Roles of nAChR in mediating Aβ toxicity.  
NR1: α7-nAChR; and NR2: non-α7-nAChR; ER: endoplasmic reticulum. Soluble 
Aβ1-42 accumulation: (1) activates α7-nAChR and induces Ca2+ influx through this 
receptor and increases Ca2+ release from intracellular Ca2+ pool (ER); together, 
these effects cause elevation in the intracellular Ca2+ concentration; (2) 
intracellular α7-nAChR combines with Aβ (co-localization) to  favor intracellular 
plaque formation; (3) Aβ activates presynaptic α7-nAChR located on 
glutamatergic terminals and increases glutamate release, which activates 
ionotropic glutamate receptors and leads to Ca2+ influx via both the 
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NMDA receptor and voltage-gated Ca2+ channels; and (4) Aβ suppresses non-α7-
nAChR and causes receptor upregulation. These more highly expressed non-α7-
nAChR (mostly α4β2-nAChR) can be activated by endogenous ACh to depolarize 
the membrane potential, which leads to the Ca2+ influx via both unblocked 
NMDA receptors and voltage-gated Ca2+ channels. Together, Aβ acts on neuronal 
nAChR and directly and/or indirectly elevates intracellular Ca2+ concentrations, 
which triggers neuronal degeneration through the Ca2+-dependent signal cascades. 
 
1.4 α7-nAChR and Aβ induced neuronal hyperexcitation 
 
1.4.1 α7-nAChR function and expression were up-regulated by Aβ 
In findings suggesting possible pathophysiological links between Aβ, nAChR and 
AD, Wang et al. (Wang et al., 2000b; Wang et al., 2000a) reported very high 
affinity binding of Aβ1-40 and Aβ1-42 to α7-nAChR. Two other groups reported 
direct and functionally-relevant interactions of Aβ1-42 with α7-nAChR (Liu et al., 
2001; Pettit et al., 2001). Thereafter, several groups, including ours, reported the 
effects of Aβ on α7-nAChR (Wu et al., 2004; Liu et al., 2009). Most in vitro 
studies show an inhibitory effect of acute application of Aβ on native α7-nAChR 
expressed by neurons in culture or brain slices and on heterologously-expressed 
α7-nAChR in transfected cells (Liu et al., 2001; Pettit et al., 2001; Grassi et al., 
2003; Wu et al., 2004; Lamb et al., 2005; Spencer et al., 2006; Liu et al., 2009). In 
addition, mounting evidence indicates that activation of α7-nAChR 
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significantly enhances cognitive function (Levin and Rezvani, 2002). Taken 
together, this evidence has established the concept that in AD, impairment of α7-
nAChR function by Aβ inhibition contributes to cholinergic signaling deficits and 
cognitive decline, and that enhancement of α7-nAChR function would be a 
therapeutic strategy in treatment of AD (Bencherif and Schmitt, 2002; Buccafusco 
et al., 2005; D'Andrea and Nagele, 2006; Buckingham et al., 2009). Furthermore, 
although Aβ inhibits α7-nAChR acutely, these receptors exhibit enhanced 
expression (mRNA and protein) in both AD patients and AD model animals 
(Hellstrom-Lindahl et al., 1999; Dineley et al., 2002b; Hellstrom-Lindahl et al., 
2004b; Hellstrom-Lindahl et al., 2004a; Teaktong et al., 2004; Chu et al., 2005; 
Jones et al., 2006; Counts et al., 2007), and functionally, α7-nAChR-mediated 
currents are at least comparable between APP transgenic and wild-type mice at 
adult (7 months) ages (Spencer et al., 2006). The possible interpretation is that the 
inhibition of α7-nAChR by Aβ may trigger receptor up-regulation (Molinari et al., 
1998). These data suggest that α7-nAChR may exhibit hyper- rather than hypo-
expression and function in hippocampal neurons in AD model animals or even in 
AD patients. This new concept has important clinical significance, (Counts et al., 
2007; Leonard and McNamara, 2007) in part because: (1) α7-nAChR exhibit 
extremely high permeability to Ca2+ (Couturier et al., 1990; Bertrand et al., 1992), 
and intracellular Ca2+ overload triggers neurodegeneration. (2) Activation of α7-
nAChR facilitates internalization of Aβ (Nagele et al., 2002) and NMDA 
receptors (Snyder et al., 2005), which contributes to cytotoxicity and synaptic 
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impairment. (3) Activation of α7-nAChR facilitates presynaptic glutamate release 
and increases neural excitability and seizure activity, and leads to cell death via 
excitotoxicity (Counts et al., 2007; Leonard and McNamara, 2007; Palop and 
Mucke, 2009). (4) Animals with gain-of-function α7-nAChR mutations exhibit 
significantly higher susceptibility to epileptic seizures (Broide et al., 2002). (5) 
Uncoupling of Aβ interactions with α7-nAChR significantly eliminates Aβ 
toxicity (Wang et al., 2009a). (6) Genetic deletion of nAChR α7 subunits 
significantly restores synaptic impairment and learning/memory deficit in APP 
mice (Dziewczapolski et al., 2009). (7) Several therapeutic medications for AD 
such as cholinesterase inhibitors, memantine, or kynurenic acid are potent 
antagonists of α7-nAChR (Clarke et al., 1994; Aracava et al., 2005; Lopes et al., 
2007). (8) One recent report shows that an α7-nAChR agonist protects cholinergic 
function in wild-type but not APP transgenic mice (Ren et al., 2007). Collectively, 
these lines of evidence suggest that over expression and hyperfunction of α7-
nAChR, perhaps induced by Aβ exposure, contributes to AD pathology, and that 
attenuation of α7-nAChR function could be a new strategy for the treatment of 
AD.  
 
1.4.2 Roles of α7-nAChR in neural hyperexcitation and synchronization 
Accumulating evidence suggests that the activation of α7-nAChR plays a role in 
the modulation of neuronal excitability and synchronization. From molecular 
level, the region encompassing the gene for the α7 subunit might be a susceptible 
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locus for juvenile myo-clonic epilepsy (Elmslie et al., 1997; Neubauer et al., 1998; 
Neubauer, 2000). Pharmacological experiments demonstrate a positive correlation 
between the number of α-bungarotoxin (α-BTX) binding sites in the hippocampus 
and sensitivity to nicotine-induced seizures (Miner et al., 1984, 1985; Miner and 
Collins, 1989). It has been reported that α7-nAChR is important in mediating 
nicotine-induced seizures (Damaj et al., 1999). In addition, mutant mice harboring 
a gain-of-function mutation of α7-nAChR (L250T α7-nAChR) have increased 
sensitivity to both spontaneous, and nicotine-induced, seizures (Broide et al., 2002; 
Gil et al., 2002). Moreover, a selective α7-nAChR ligand, NJ403, exhibits 
anticonvulsant properties (at high doses) probably through desensitization of α7-
nAChR (Feuerbach et al., 2009). Together, these data suggest that α7-nAChR 
likely play an important role in neural excitation and synchronization. On the 
other hand, there are also some controversial reports. For instance, one report 
showed that α7 nAChR subunit-null mice were no less sensitive to the convulsive 
effects of nicotine-induced seizures than wild-type mice (Franceschini et al., 
2002). Nevertheless, evaluation of the roles of α7-nAChR in Aβ-induced neural 
hyperexcitation and epileptic seizures is significant and novel, and such 
evaluation may provide new insights into the mechanisms of Aβ toxicity and AD 
pathogenesis.  
 
1.5 Goals of This Dissertation 
Patients with AD (Govind et al., 2009) exhibit a significantly higher incidence of 
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unprovoked seizures compared to the age-matched non-AD controls, and animal 
models of AD display neural hyper-excitation and epileptic seizures (Hesdorffer 
et al., 1996; Mendez and Lim, 2003; Amatniek et al., 2006; Lozsadi and Larner, 
2006; Palop et al., 2007; Busche et al., 2008; Hommet et al., 2008; Westmark et 
al., 2008; Larner, 2009; Minkeviciene et al., 2009; Palop and Mucke, 2009a). 
Neuronal hyperexcitation is particularly important, because it contributes to the 
high incidence of epilepsy in AD patients (Palop and Mucke, 2009a) as well as 
AD-related synaptic deficits and neurodegeneration (Broide et al., 2002; Palop 
and Mucke, 2009a, b). Given that there is significant Aβ accumulation and 
deposition in AD brain, Aβ exposure ultimately may be responsible for neural 
hyper-excitation in both AD patients and animal models.  
 
In addition, there is evidence that α7 nicotinic acetylcholine receptors (α7-nAChR) 
are involved in AD pathology, because synaptic impairment and learning and 
memory deficits in a hAPPα7-/- mouse model are decreased by nAChR α7 subunit 
gene deletion (Dziewczapolski et al., 2009). Given that Aβ potently modulates 
α7-nAChR function (Liu et al., 2001; Pettit et al., 2001; Grassi et al., 2003; Wu et 
al., 2004a; Lamb et al., 2005; Spencer et al., 2006; Liu et al., 2009), that α7-
nAChR expression is significantly enhanced in both AD patients and animal 
models (Hellstrom-Lindahl et al., 1999; Dineley et al., 2002b; Hellstrom-Lindahl 
et al., 2004b; Hellstrom-Lindahl et al., 2004a; Jones et al., 2006; Counts et al., 
2007; Ikonomovic et al., 2009), and that α7-nAChR play an important role in 
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regulating neuronal excitability (Dani, 2000; Sher et al., 2004; McKay et al., 
2007), it is reasonable that α7-nAChR may contribute to Aβ-induced neural 
hyperexcitation. The fundamental goal of this project is to elucidate mechanisms 
of Aβ-induced neural hyperexcitation. We hypothesize that increased α7-nAChR 
expression and function as a consequence of Aβ exposure is important in Aβ-
induced neural hyperexcitation in in vitro and in vivo AD models. We test our 
hypothesis using multiple experimental approaches including electrophysiology 
and cell/molecular biology in wild-type (WT), Triple-Transgenic (hAPP/PS1/Tau) 
and nAChR α7 knockout (α7-/-) mice. 
 
The key issue is to reveal the roles of α7-nAChR in Aβ–induced neural 
hyperexcitation and underlying mechanisms, which likely contribute to high 
incidence of epilepsy in AD patients and Aβ pathology.  The project tests this 
novel hypothesis and provides a better understanding of how epileptic seizures 
occur in AD, and identifies targets involved in Aβ-induced epileptic seizures. 
Knowledge gained will improve our understanding of possible etiopathogenic 
mechanisms involving Aβ. This work will also aid the selection of superior 
strategies for pharmaceutical development to prevent or attenuate Aβ 
neurotoxicity. Results from this project not only would it help to explain the high 
incidence of epilepsy in AD, but it also would point to novel targets, perhaps α7-
nAChR, for early therapeutic intervention.   
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Chapter 2 
Aβ-INDUCED NEURONAL HYPEREXCITATION 
 
2.1 Introduction 
 
There is abundant evidence indicating that high-levels of Aβ induce neuronal or 
neurocircuit hyperexcitation. AD patients and animal AD models exhibit epileptic 
seizures (Hesdorffer et al., 1996; Mendez and Lim, 2003; Amatniek et al., 2006; 
Lozsadi and Larner, 2006; Palop et al., 2007; Busche et al., 2008; Hommet et al., 
2008; Westmark et al., 2008; Larner, 2009; Minkeviciene et al., 2009; Palop and 
Mucke, 2009a). Aberrant accumulation and deposition of Aβ are thought to 
induce this pathology (Minkeviciene et al., 2009). However, the precise 
underlying mechanisms of Aβ induction of neuronal or neurocircuit 
hyperexcitation are largely unknown. For instance, chronic exposure to high 
levels of Aβ sensitizes some neuronal networks to hyperexcitation (Del Vecchio 
et al., 2004). In animals that over-express Aβ, the high-levels of Aβ peptide cause 
epileptiform activity within the entorhinal-hippocampal circuitry (Palop et al., 
2007). Westmark et al. (Westmark et al., 2008) compared seizure threshold (test 
response to pentylenetetrazol, PTZ) between AD model animals (Tg2576) and 
wild-type mice, and found a reduction of seizure threshold in AD model animals. 
By studying the mechanisms of neuronal hyperexcitation in AD model animals, 
Busche et al. (Busche et al., 2008) found that impaired synaptic inhibition, rather 
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than Ca2+ release from intracellular stores, or intrinsic firing underlie neuronal 
hyperactivity. These lines of evidence suggest that Aβ induces neuronal 
hyperexcitation. Elucidation of the selective targets and underlying mechanisms 
in Aβ induced neuronal hyperexcitation will provide important insights into the 
pathogenesis of AD and also could open new therapeutic avenues. 
 
To elucidate the mechanisms that cause neural hyperexcitation, it is essential to 
establish an in vitro cell model, in which Aβ can induce a neuronal 
hyperexcitation, and which can be used to investigate underlying mechanisms. We 
hypothesize that although acute Aβ mostly suppresses neuronal activity and 
network synchronization (Wang et al., 2009), chronic Aβ exposure may increase 
neuronal excitability. We test this hypothesis using patch-clamp recordings in 
primary cultured hippocampal neurons, chronically treated with Aβ. We will 
determine neuronal excitability by measuring intrinsic and synaptic changes after 
chronic Aβ exposures.  
 
2.2 Materials and Methods  
 
2.2.1 Primary cell culture 
The protocol for preparation of neuronal cultures from rodents was approved by 
the Institutional Animal Care and Use Committee of the Barrow Neurological 
Institute and St. Joseph's Hospital and Medical Center. The day before culture, 
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poly D-lysine 0.02% solution was added to culture dishes. Dishes were swirled to 
make sure that the entire bottom was coated and then dishes were left in the 
37˚C/5% CO2 incubator overnight. On the next day of culture, dishes were 
washed three times with sterile water and left in the incubator after the final wash. 
1~3 day-old postnatal Wistar rat or C57BL/2 mice were sacrificed, and 
hippocampus regions containing the CA1 and CA3 were dissected under a 
stereological microscope. Tissue was minced with scissors in ice-cold Neurobasal 
medium (Invitrogen, Carlsbad, CA) and then digested with Papain (20unit/mg, 
Worthington, Lakewood, NJ) at 30oC for 20 min in tubes shaken at 120 rpm in a 
waterbath shaker. After enzyme digestion, the reaction was ceased by adding 
inactivated fetal bovine serum into the medium. Then, digested tissue was filtered 
and transferred into 15 ml tubes. After trituration, tissue was centrifuged at 1500 
rpm for 3 min to form pellets containing dissociated cells, and the supernatant was 
removed and replaced with Neurobasal medium, which was used to resuspend the 
pellets. This process was repeated 3 times. After the final centrifugation, the 
supernatant was replaced with Neurobasal medium supplemented with 0.5% (w/v) 
L-glutamine and 2% B27 serum-free supplement. Cells were resuspended and 
counted based on Trypan blue exclusion and plated at a density of 4.5-5.0X104 
cells per cm2 in 35mm culture dishes. Cells were kept within the 37˚C/5% CO2 
incubator for future use. 
 
2.2.2 Electrophysiology 
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The standard external solution contained 140 mM NaCl, 3 mM KCl, 2 mM 
MgCl2, 2 mM CaCl2, 10 mM d-glucose, 10 mM HEPES, adjusted to pH 7.4 with 
Tris base. The internal solution for current-clamp recordings to measure intrinsic 
excitability contained 130 mM KMeSO4, 10 mM KCl, 10 mM HEPES/K-HEPES, 
2 mM MgSO4, 0.5 mM EGTA and 3 mM ATP; the pH was adjusted to 7.3 with 
KOH. For miniature EPSC (mEPSC) recordings, 0.3 µM TTX, 50 µM picrotoxin, 
and 50 µM APV were added into external solution. For whole-cell recordings of 
ligand-gated ion channels and miniature EPSC (mEPSC) recordings, the internal 
solution contains the following: 140 mM potassium gluconate, 5 mM KCl, 10 
mM HEPES, 0.2 mM EGTA, 2 mM MgCl2, 4 mM MgATP, 0.3 mM Na2GTP 
and 10 mM Na2-phosphocreatine (pH 7.3 with KOH). Data were acquired by 
Axonpatch 200B amplifier at 2 kHz with pClamp 9.2 software (Molecular 
Devices, Sunnyvale, CA) and analyzed with clampfit 9.2 software (Molecular 
Devices, Sunnyvale, CA) and Mini Analysis software (Synaptosoft, Decatur, GA).  
 
Hippocampal slices were prepared from WT and age-matched (18-20 months) 
3xTgAPP mice in accordance with Institutional Animal Welfare Committee 
guidelines. Under isoflurane-induced anesthesia, brain tissue was quickly 
removed and bathed in ice-cold (4 °C) artificial cerebrospinal fluid (ACSF) 
composed of (in mM): 124 NaCl, 3 KCl, 26 NaHCO3, 1.3 MgSO4, 1.2 NaH2PO4, 
2.4 CaCl2, and 10 glucose; bubbled with 95% O2–5% CO2. Several 450 μm 
coronal sections containing the dorsal hippocampus were cut and transferred to a 
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pre-incubation chamber and incubated at room temperature in ACSF for 60 min. 
Standard extracellular field potential recordings were performed from the 
hippocampal CA1 cell layer using borosilicate glass micropipettes pulled to a tip 
diameter of about 1 μm and back-filled with 2 M NaCl. For tetanic stimulation-
induced field potential responses, stimulation consisted of a train of 100 Hz pulses 
(each single pulse having a duration of 100 μs) for 200 ms using a Model 2100 
isolated pulse stimulator (A-M Systems, Inc., Carlsborg, WA, USA). Field 
potential responses were recorded using an Axoclamp-2B amplifier (Axon 
Instruments, Foster City, CA, USA). Single pulse (20–30 V, 100 μs) stimulation-
induced field potential responses were measured 1 min prior to tetanic stimulation 
to ensure that the slice was viable and that normal synaptic transmission was 
stable. After observing at least three consecutive, stable single responses, tetanic 
stimulation-induced responses over 60 min were monitored. Data were acquired 
by Clamplex 9.2 via a Digidata 1322 series A/D board set to a sampling 
frequency of 10 kHz, and filtered in Clampfit 9.2 (Axon Instruments) using an 8-
pole Bessel filter and a 1-kHz low-pass filter. The power of the induced responses 
in the γ-frequency spectrum was calculated off-line using Fast Fourier Transform 
(FFT) in Clampfit 9.2. Statistical comparisons of results were performed using 
Origin 7.0 (Microcal Software, Inc., Northampton, MA, USA).  
 
2.2.3 Drugs, Aβ preparation, and Aβ treatment 
Drugs used in this study are choline (Sigma, St. Louis, MO), scrambled Aβ1-42, 
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and Aβ1-42 (rPeptide, Athens, GA). Aβ1-42 peptides were dissolved in 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP) at a concentration of 1 mg/mL in 250 μl aliquots, 
air dried and stored at –20 °C. Aliquots were resuspended in dimethyl-sulfoxide 
(DMSO) and further diluted in phosphate buffered saline (PBS), pH 7.4, to a final 
concentration of 100 μM and incubated at 37 °C without shaking. Oligomeric 
aggregates of Aβ1-42 were obtained after incubation for 6 h. For fibril formation, 
Aβ1-42 was incubated at 37 °C for at least 96 h for Aβ1-42. Both oligomeric and 
fibrillar forms were verified by atomic force microscopy (AFM) before being 
added into culture medium. Primary cultured neurons were maintained at 37 °C in 
a humidified atmosphere of 5% CO2/95% air for 10 days before Aβ1-42 treatments. 
Aβ1-42 treatment was performed by renewing Aβ1-42-containing culture medium 
(100 nM) daily for 3-10 days. The same renewal procedure with medium 
containing scrambled Aβ1-42 was performed as a control. Aβ used in this project 
was all Aβ1-42. Aβ 1-42 is abbreviated as Aβ.  
 
2.2.4 Electron Microscopy (EM) 
The aggregation forms of Aβ42 used in this project was examined by negative-
stain electron microscopy immediately before use. 2 μl from 100 μM samples was 
adsorbed to the surface of a plasticcoated, carbon-backed, 300-mesh copper grid 
for 1 min; blotted to remove excess liquid; and covered with 5 μl of 2% aqueous 
uranyl acetate for 2 min; then, excess liquid was removed, and the sample was 
allowed to air dry. Samples were viewed at 340,000–175,000 magnification using 
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a Philips CM12 electron microscope, and images were collected with an AMT 
XR40 digital camera (Advanced Microscopy Techniques Corp., Danvers, MA). 
Sizes were calibrated with catalase crystals (Ted Pella, Redding, CA). 
 
2.2.5 Atomic force microscope (AFM) imaging  
AFM was used to monitor the morphology of the Aβ aggregates before 
experiments. Aliquots were removed from Aβ samples, and then immediately 
spotted on freshly cleaved mica. After 2 min the mica was washed with 1 mL of 
de-ionized water, and then dried with compressed nitrogen. Topographic AFM 
images were obtained in air at room temperature using a Tapping Mode AFM 
with a Nanoscope IIIa controller (Veeco, Santa Barbara, CA).  Images were 
acquired using oxide sharpened Si3N4 AFM tips (k = 40 N/m, fo ~ 300kHz) 
(Model: OTESPA, Veeco, Santa Barbara, CA) at scan rates of 2-3 Hz and at scan 
resolution of 512 samples per line. Images were subjected to 2nd order polynomial 
flattening as needed to reduce the effects of image bowing and tilt. AFM images 
were analyzed with the Scanning Probe Imaging Processor (SPIP) software 
(Image Metrology, www.imagemet.com) to generate height distribution 
histograms for each sample. 
 
2.2.6 Immunostaining 
Cells from hippocampal neuronal cultures (14–21 d in vitro) were injected with 
biocytin (5 mg/ml, included in recording electrodes and infused into the 
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intracellular space at the end of the recording session by converting to the true 
whole-cell recording mode) while in their 35 mm culture dishes.  After recordings, 
cells were fixed in 4% paraformaldehyde for 10 min and washed with PBS 3 
times 5 min at room temperature. Then, a PBS-based blocking solution containing 
5% normal goat serum and 0.3% Triton X-100 was applied for 1 h. After 
incubations at 4°C overnight with the primary goat anti-neurogranin antibody 
(1:100 dilution; Santa Cruz Biotechnology, Santa Cruz, CA), the cultures were 
then washed with PBS three times for 5 min. Thereafter, Avidin AF488 (1:1000 
dilution; Invitrogen, Carlsbad, CA) was added to identify fluorescently label 
biocytin-containing cells that were subject to recording, and the neurogranin 
secondary antibody, Alexa 555-conjugated anti-goat IgG Invitrogen), was applied 
in blocking solution for 2 h at room temperature to confirm identity of pyramidal 
neurons.  The cultures were then finally washed three times for 5 min with PBS. 
 
2.2.7 Mice 
Mice of the 3×Tg–AD strain were developed by Oddo and LaFerla (Oddo et al., 
2003). To generate these transgenic mice, human APP cDNA harboring the 
Swedish mutation (KM670/671NL) and human four-repeat Tau harboring the 
P301L mutation were co-microinjected into single-cell embryos of homozygous 
presenilin 1 (PS1M146V) knockin mice. The background of the PS1 knockin mice 
was a hybrid 19/C57BL6 strain. This transgenic model produces amyloid-β (Aβ) 
   
35
plaques preceding the formation of neurofibrillary tangles with clear phenotypes 
of the cognitive behavior and memory deficit starting from the early stage of their 
life (Oddo et al., 2003). The transgenic mice used in this study were all of the 
same genetic and strain background. Experiments were performed under protocols 
approved by the Institutional Animal Care and Use Committee at the Barrow 
Neurological Institute, St. Joseph's Hospital and Medical Center. Transgenic 
status of mice was blinded until the experiments were completed. PCR 
genotyping was performed to confirm the genetic status of these mice. Mice were 
group-housed in plexiglass shoebox-style cages with access to food and water. 
 
2.2.8 EEG recording 
EEG recordings were performed on WT and age-matched (18-20 months) 
3xTgAPP mice. In these experiments, EEG was recorded continuously for 1 week 
using a 128 channel Beehive® Horizon long-term EEG monitoring machine 
(Grass Technologies, RI, US). The EEGs were read and seizures were determined 
by visual inspection of the EEG.  
 
2.2.9 Golgi staining and analysis of dendritic morphology in vivo  
Golgi staining was performed on WT and 3xTg mice. For these experiments, we 
used the FD Rapid Golgi Stain kit (FD NeuroTechnologies, Ellicott City, MD). 
Freshly dissected brains were immersed in solution A and B for 2 weeks at room 
temperature and transferred into solution C for 24 h at 4°C. The brains 
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were sliced using a Vibratome (VT1000S; Leica) at a thickness of 150 μm. 
Bright-field microscopic (Axioplan 2, Zeiss) images (at 63× magnification) were 
taken of pyramidal neurons in CA1. To analyze the branch numbers, Scholl 
analysis was performed by counting the number of dendrite intersections for 
concentric circles of gradually increasing radius centered at the soma. Images 
were coded, and dendritic spines were counted in a blinded manner using 
Neurolucida software (MicroBrightField, San Diego, CA). 
 
2.2.10 Data analysis and statistics 
Data were given as mean ± SEM with numbers (n). A probability level of p<0.05 
was considered to be statistically significant. Significant differences were 
determined using the two-tailed Student’s t-test or one-way ANOVA as 
appropriate. 
 
2.3 Results 
 
2.3.1 Identification of pyramidal neurons for recording 
Primary cell cultures from the hippocampus of rats or mice at 1-3 d old were used. 
Pyramidal cells within these cultures were initially chosen based on their 
morphology and reference to their firing behavior after initial patching. Postburst 
sAHPs longer than 1 sec were observed in most of these neurons as previously 
described (Shah et al., 2002). After patch clamp recording, biocytin was injected 
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through the pipette solution, and identification was finally confirmed by post-
experiment immunostaining with an anti-neurogranin (a marker for pyramidal 
neurons) antibody.  
 
Typical pyramidal neurons (Figure 2 Aa and b) were identified based on their 
slow firing behavior (<10 Hz) with spike-frequency adaptation (Figure 2 Bb, blue 
trace). Firing patterns of these neurons are slower than typical non-pyramidal cells 
negative for neurogranin immunostaining (Figure 2 Ac, d, and Bb, black trace).  
Most pyramidal neurons express functional α7-nAChR (43 of 48 neurons 
recorded). The choline (10 mM) induced current density of α7-nAChR expressed 
in pyramidal neurons was comparable to that for nAChR expressed in non-
pyramidal cells (19 of 28 neurons recorded), but the number of spikes elicited by 
current injection was significantly lower in pyramidal neurons than in non-
pyramidal neurons (Figure 2 Ba and c. two-tailed student t-test, p<0.01).  
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Figure 2 Identification of pyramidal neurons for recording  
A: Typical pyramidal neuron (Aa and b) and non-pyramidal neuron (Ac and d) 
were identified by biotin microinjection and post-recording neurogranin 
immunostaining. B: Representative traces and calculated parameters from 
pyramidal and non-pyramidal neurons. Choline 10 mM induced whole-cell current 
in pyramidal and non-pyramidal neurons (Ba and c). Number of spikes elicited by 
current injection was significantly lower in pyramidal neurons than in non-
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pyramidal neurons (Bb and c, **p<0.01). 
 
2.3.2 Aβ preparation and Aβ treatment 
EM and AFM were used to monitor aggregation forms of Aβ in this study. 
Preparations of Aβ in the form of oligomers (100 nM, 24 hr) contained short, 
irregular rods, globules, and some rings as evident in EM (Figure 3 A) and AFM 
(Figure 3 C) images. Fibril preparations are enriched for long fibrils. Bars = 100 
nm, in Figure 2.3 B and D (100 nM, 24 hr). 
 
 
Figure 3 Electron and atomic force microscopic analyses of Aβ preparations  
Different physical forms of Aβ were prepared as described above. A: Preparations 
in the form of oligomers contained short, irregular rods, globules, and some rings. 
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B: Samples made to form aggregates were highly enriched for long fibrils. Bars = 
100 nm, in both panels. C and D: AFM image shows the forms of oligomers and 
fibrils of Aβ after preparation (100 nM, 24 hr).  
 
2.3.3 Chronic Aβ treatment induces neuronal hyperexcitation 
Mounting evidence has indicated that long-term exposure to Aβ may cause 
neuronal hyperexcitation and degeneration (Mendez and Lim, 2003; Palop et al., 
2007; Larner, 2009; Palop and Mucke, 2009b). First of all, we compared effects of 
different forms of Aβ on neuronal excitability. After treating the cultured 
hippocampus neurons with scrambled, monomeric, oligomeric or fibrillar Aβ (100 
nM), for 7 days, we measured the intrinsic excitability in neurons injected with a 
90 pA pulse current. After chronic treatment, hippocampal pyramidal neurons 
treated with Aβ fibrils, and to a lesser extent, Aβ oligomers, exhibited 
significantly increased, intrinsic excitability (Fig. 4). Aβ fibril treatment 
dramatically increased spike numbers (*p<0.05, **p<0.01, one-way ANOVA; Fig 
4 B). Aβ fibril treatment significantly enhanced the elevation in membrane 
potential induced by pulse injection (**p<0.01, one-way ANOVA; Figure 4 C). 
These results suggest chronic Aβ treatment, particularly Aβ fibril treatment, can 
increase intrinsic excitability in cultured hippocampus pyramidal cells.  
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Figure 4 Chronic Aβ treatment induces neuronal hyperexcitation.  
A. Typical traces show that after chronic treatment with different forms of Aβ at 
100 nM for 7 days, hippocampal pyramidal neurons treated with Aβ fibril 
exhibited increased intrinsic excitability.  Intrinsic excitability was measured by 
using an injection of 90 pA pulse into these neurons. B. Bar graph summarizes 
number of spikes counted from neurons injected with 90 pA pulse after treatment 
with different forms of Aβ for 7 days. Both oligomer and fibril treatment 
significantly increased spike numbers (*p<0.05, **p<0.01). C. Bar graph 
summarizes elevated membrane potentials from neurons injected with 90 pA pulse 
after treatment with different forms of Aβ for 7 days. Only Aβ fibril treatment 
significantly enhanced the elevation of membrane potential induced by pulse 
injection (**p<0.01). 
 
Scr Mon Oli Fib 
   
42
2.3.4 Aβ fibril-induced neuronal hyperexcitation is concentration-dependent 
Then, we asked whether or not Aβ fibril-induced neuronal hyperexcitation is 
concentration-dependent. Thereafter we treated the cultured hippocampal neurons 
with 1 nM, 10 nM, 100 nM, or 1 μM Aβ fibrils, and then compared sensitivity to 
current injection-induced membrane excitability. Results show that at 
concentrations of 100 nM and 1 μM, but not at 1 nM or 10 nM, Aβ fibril treatment 
for 7 days can increase intrinsic excitability (Figure 5 A). Exposure to 100 nM or 
1 μM of Aβ fibril significantly increased spike number after 7 days treatment 
(**p<0.01, two-tailed Student’s t-test; Figure 5B).  100 nM or 1 μM Aβ fibril 
treatment significantly enhanced the increase in membrane potential induced by 
90 pA pulse injection (**p<0.01, one-way ANOVA; Figure 5 C).  
 
 
 
Figure 5 Aβ fibril induced neuronal hyperexcitation is dose-dependent. 
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A: Sample traces of effects of 1 nM, 10 nM, 100 nM, or 1 μM Aβ fibril exposure 
on membrane excitability recorded from hippocampal pyramidal neurons. B: Bar 
graph summarizing the data shows that 100 nM or 1 μM Aβ fibril exposure 
significantly increased spike number after 7 days treatment (**p<0.01).  C: Bar 
graph summarizing the data shows that membrane potential changes are more 
pronounced in neurons injected with a 90 pA current pulse after treatment with 
100 nM or 1 μM Aβ fibril for 7 days (**p<0.01).  
 
2.3.5 Time-course of Aβ fibril-induced increase of intrinsic excitability 
To examine the time course of Aβ-induced increases in intrinsic excitability, 
hippocampal neurons were treated with 100 nM Aβ fibril for different periods of 
time; i.e., 0, 1, 4, 7, or 10 days (Figure 6 A). Treatment with 100 nM Aβ fibrils for 
7 or 10 days significantly increased spike number (Figure 6B) and the change in 
membrane potential after injection of a 90 pA current pulse (Figure 6C; **p<0.01, 
two-tailed Student’s t-test).  These findings together indicate that Aβ, particularly 
in the fibrillar form, can cause hyperexcitation in hippocampal pyramidal cells. 
Based on above results, we utilized 100 nM Aβ fibrils and 7 days of treatment to 
establish Aβ’s effects on neuronal hyperexcitation. 
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Figure 6 Time-course of Aβ fibril induced increase of intrinsic excitability. 
A: Sample traces of effects of 100 nM Aβ fibrils on membrane excitability 
recorded from hippocampal pyramidal neurons for the indicated periods (0, 1, 4, 7 
or 10 days). B: Bar graph indicates that 100 nM Aβ fibril exposure significantly 
increased spike number after 7 or 10 days of treatment (**p<0.01, two-tailed 
Student’s t-test).  C: Bar graph indicates that elevated increases in membrane 
potential change occur in neurons injected with 90 pA pulse after treatment with 
Aβ fibrils for 7 or 10 days (**p<0.01, two-tailed Student’s t-test).   
 
2.3.6 Increased input–output ratio and membrane potential elevation levels 
after chronic Aβ treatment 
Under control conditions, hippocampal pyramidal neuron cultures treated with 100 
nM scrambled Aβ displayed a relatively low frequency of spiking 
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activity after current injection (Figure 7 Aa). However, after exposure to 100 nM 
Aβ fibrils for 7 days, these cells exhibited increased spiking activity after current 
injection (Figure 7 Ab).  The differences observed were statistically significant 
(Figure 7 B; p < 0.01, two-tailed Student’s t-test). We also utilized input–output 
(I/O) relationships defining the number of action potentials elicited as a function 
of injected, depolarizing current intensity to evaluate membrane excitability. Aβ 
fibril treatment caused significantly increased membrane potential changes at a 
given level of current injection than seen in control samples treated with 
scrambled Aβ (Figure 7 C; Aβ fibril: 13.57 ± 1.60 mV, n = 10; Aβ scramble: 9.43 
± 0.76 mV, n = 8; p < 0.01).  
 
 
 
 
Figure 7 Chronic Aβ fibril treatment increases intrinsic excitability  
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Mature, cultured hippocampal pyramidal neurons (DIV Day 22) were treated with 
100 nM Aβ fibrils or scrambled Aβ for 7 days starting on DIV Day 15. A: After 
exposure to Aβ fibrils for 7 days, hippocampal pyramidal neurons exhibited 
increased spiking activity after current injection (Aa and b) when compared with 
scrambled Aβ-treated controls. B: Analysis of input-output relationships between 
current injection and number of spikes from pyramidal neurons treated with Aβ 
fibrils or scrambled Aβ shows that these effects were seen regardless of the 
injected current level (*p<0.05, **p<0.01, two-tailed Student’s t-test). C:  Aβ 
fibril treatment also elevated membrane potential changes after 90 pA current 
injection (**p<0.01, two-tailed Student’s t-test). 
 
2.3.7 Aβ-treatment increases neuronal synaptic activity 
To examine whether fibrillar Aβ-induced increases in membrane excitability and 
bursting activity affect excitatory synaptic transmission, we recorded AMPA (2-
amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl) propanoic acid) receptor-mediated 
mEPSCs from cultured pyramidal neurons. A significant and steady increase in 
mEPSC frequency was observed after 100 nM Aβ fibril treatment relative to 
scrambled Aβ-treated controls (Figure 8 A and B; Aβ fibril: 5.82 ± 0.33 Hz, n = 10; 
Aβ scrambled: 4.21 ± 0.27 Hz, n = 8; p < 0.01), while the mEPSC amplitude was 
not changed (Figure 8 A and B; Aβ fibril: 38.26 ± 3.19 pA, n = 10; Aβ scrambled: 
35.82 ± 3.56 pA, n = 8; *p < 0.05). The increase in mEPSC frequency may be due 
to a higher probability of vesicular glutamate release. These results suggest that 
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Aβ fibril treatment can modulate presynaptic vesicular glutamate release to cause 
potentiation of both membrane excitability and excitatory synaptic transmission. 
 
 
 
Figure 8 Chronic Aβ treatment increases neuronal synaptic activity. 
Mature, cultured hippocampal neurons (DIV Day 22) were treated with 100 nM 
fibrillar or scrambled Aβ for 7 Days starting on DIV Day 15. A: Sample traces of 
mEPSC recorded from cultured pyramidal neurons exposed to Aβ fibril (Ab) or 
scrambled Aβ (Aa) for 7 days. B: Significantly increased mEPSC frequency but 
not mEPSC amplitude was observed in pyramidal neurons after treatment with Aβ 
fibrils compared to scrambled Aβ-treated controls (Ba and b; *p<0.05, **p<0.01, 
two-tailed Student’s t-test). 
 
   
48
2.3.8 Human APP transgenic mice (3xTg) exhibit epileptic seizures and 
impaired synaptic plasticity 
To examine whether or not aged APP mice exhibit seizure activity, we performed 
electroencephalography (EEG) recordings from two 3xTgAPP mice and two age-
matched (18-20 months) WT mice. The results (Figure 9) show seizure activities 
in 3xTgAPP but not WT mice manifest as a higher likelihood of spike waves 
(SWs). After EEG recordings, long-term potentiation (LTP) experiments were 
performed on hippocampal slices from the same mice. LTP was induced by three 
theta-burst trains (5 trains with 100 Hz for 10 times at the interval of 200 ms) 
separated at 20 sec intervals. The results showed that LTP in aged 3xTgAPP 
hippocampal CA1 slice was significantly impaired (n=3 slices from 2 mice) 
compared to those from age-matched WT mice (n=4 slices from 2 mice).  
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Figure 9 Abnormalities of neuronal network synchronization and synaptic 
plasticity in 3xTgAPP mice.  
A: Representative traces of EEG recordings from either WT (Aa) or 3xTgAPP 
mice (Ab). B: Field excitatory postsynaptic potential (fEPSP)-population spike 
was examined. The results show impaired LTP in 3xTgAPP mice (n=3) 
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compared to WT mice (n=4). The same animals were used in A and B. 
 
2.3.9 3xTg mice exhibited high seizure susceptibility.  
To test whether enhanced in vivo Aβ expression induces hippocampal 
hyperexcitation, we performed field recordings in the CA1 region of hippocampal 
slices prepared from 3xTg-AD mice (Oddo et al., 2003). We compared cabarchol 
(CCh)-induced network synchronization in 10-month-old 3xTg-AD and age-
matched WT mice. In 9 slices tested from 3 AD mice, 6 slices exhibited θ-
oscillations (Figure 10 A), whereas in 10 slices tested from 3 WT mice, only 3 
slices had θ oscillations (Figure 10 B) after bath-perfusion of 50 μM CCh for 30 
min. The frequency and bursting cluster numbers of θ oscillations were 6.8±0.6 
Hz and 17.8±3.5 for AD slices and 4.3±0.7 Hz and 5.3±2.8 (p<0.05, two-tailed 
Student’s t-test) for WT slices. These results suggest that the hippocampal 
neurons/circuits in 10-month-old 3xTg-AD mice are more susceptible to CCh-
induced network synchronization.  
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Figure 10 Neural network hyperexcitation in 3xTg-AD mice.  
A: CCh (50 µM for 30 min)-induced θ-oscillations were observed in both 3xTg-
AD (Aa) and WT (Ab) mice, but 3xTg-AD mice exhibited more synchronization, 
producing a higher frequency and more clustering bursts (B). B: Increased 
frequency (Hz) and clustering bursts number of θ-oscillations were observed in 
3xTg-AD mice (*p<0.05, two-tailed Student’s t-test).   
 
2.3.10 3xTg mice have a higher number of dendritic spines than WT controls. 
To reveal the morphological basis of hippocampal hyperexcitation and 
synchronization in 3xTg APP mice, we performed Golgi staining and Scholl 
analysis to examine neuronal dendritic morphology and spine densities in 
3xTgAPP and WT mice (Jentarra et al., 2010). The results demonstrated that the 
3xTgAPP mouse hippocampal CA1 region exhibits significantly increased spine 
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density and dendritic arbor branching complexity (Figure 11 C, *p<0.05, 
**p<0.01, two-tailed student t-test). 
 
 
 
Figure 11 Morphological changes of hippocampal CA1 pyramidal neuronal 
dendrites and spines in 3xTgAPP mice.  
Golgi staining shows neuronal dendrites (A) and spines (B) in WT or 3xTg mice. 
B: Scholl analysis (a) shows that there is more complexity in spine distal from the 
soma in 3xTg mice, and there are increases in spine density (b), and in 
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branching of primary dendrites (c) and secondary dendrites (d) in 3xTg mice 
compared to WT controls (*p< 0.05, two-tailed student t-test; each symbol or bar 
is the average for measurements taken for 7 neurons from WT or 5 neurons from 
3xTgAPP hippocampal CA1 slices. 
 
2.4 Discussion 
 
Mounting evidence indicates that Aβ affects neuronal function and excitability 
(Palop et al., 2007; Wang et al., 2009a) but the results are contradictory (Klyubin 
et al., 2004; Puzzo et al., 2008). This conflict is likely caused by the wide range of 
Aβ experimental protocols used. For instance, low Aβ concentrations enhance, but 
high Aβ concentrations depress hippocampal synaptic plasticity (Puzzo et al., 
2008); oligomeric Aβ modulates neuronal function more dramatically than 
monomeric Aβ (Shankar et al., 2008); acute Aβ depresses, but chronic Aβ up-
regulates, α7-nAChR function (Liu et al., 2001; Wu et al., 2004b; Xiu et al., 2005; 
Yu et al., 2005; Liu et al., 2009). Therefore, it is very important to optimize Aβ 
experimental protocols. In addition, the characterization of Aβ in terms of 
concentration and forms expressed in this study has clinical relevance: low 
nanomolar Aβ concentrations are relevant to pathological levels in AD patients 
and animal models; oligomeric Aβ forms show more toxic effects (Hardy and 
Selkoe, 2002). In our experiments, we addressed these issues by: (1) using Aβ at 
concentrations including those in the low nanomolar range that are pathologically 
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relevant to study effects of chronic Aβ exposure on neuronal excitability, (2) we 
used EM and AFM to define different forms of Aβ used, and (3) we identified 
fibrils as an effective form to cause induce neuronal hyperexcitation.  
 
Although recent reports demonstrate that hAPP mice exhibit hippocampal circuit 
hyperexcitation and epileptic seizures (Amatniek et al., 2006; Palop et al., 2007; 
Minkeviciene et al., 2009), there is still no direct evidence that Aβ induces 
neuronal hyperexcitation. Initial experiments were designed to address this 
question. Since our preliminary experiments showed that there were no detectable 
effects of acute exposure to different forms of Aβ at nanomolar levels (1-100 nM 
for 10 min exposure) on neuronal excitability (data not shown), we tested whether 
or not chronic exposure to Aβ induces neuronal hyperexcitation. We treated 
cultured hippocampal neurons with different forms of Aβ 
(scramble/monomer/oligomer/fibril) at various concentrations (from 1nM to 1µM) 
for at least 7 days and examined neuronal excitation using patch-clamp recordings. 
Cultured hippocampal pyramidal neurons having a characteristic morphology 
usually exhibit rare spontaneous action potential (AP) firing and have 
hyperpoparizing currents(Alkondon and Albuquerque, 1995). Compared to results 
obtained when using scrambled Aβ-treated controls, Aβ fibril-treated neurons at 
concentrations over 100 nM exhibited a more positive resting membrane potential. 
Spontaneous bursting of action potentials was observed in Aβ-treated but not in 
control neurons. Input-output curves derived by injecting step currents of different 
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intensities into recorded neurons and recording membrane potential changes were 
shifted leftwards after chronic exposure to Aβ. These results indicate that chronic 
treatment of cultured hippocampal neurons with Aβ at concentrations over 100 
nM increases neuronal excitability. In addition, after chronic exposure to Aβ fibril, 
pyramidal neurons showed clearly increased AMPA receptor mEPSC frequency 
but not mEPSC amplitude. The increase in mEPSC frequency may be due to a 
higher probability of vesicular glutamate release. These results suggest that 100 
nM or higher concentration of Aβ fibril treatment can modulate presynaptic 
vesicular glutamate release to cause potentiation of both membrane excitability 
and excitatory synaptic transmission.   
 
Our results indicate that cultured hippocampal neurons are a reliable cell model to 
facilitate elucidation effects of chronic exposure on neuronal hyperexcitation and 
mechanisms involved. By using biotin microinjection plus post immunostaining 
with streptoavidin and neurogranin, we can reliably identify and phenotype the 
cells subjected to electrophysiology recording and characterization. We also show 
that in adult 3xTg mice (expressing a high level of transgenic human Aβ), the 
hippocampal network is more easily synchronized than in age-matched controls. 
These results from 3xTg mice confirm previous findings that Aβ deposition and 
accumulation will induce neuronal hyperexcitation. Taken together, these data 
support our hypothesis that chronic exposure to Aβ will induce neuronal 
hyperexcitation and hyper-synchronization both in vitro and in vivo. 
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Chapter 3 
Aβ UP-REGULATES α7-nAChR EXPRESSION AND FUNCTION 
 
3.1 Introduction 
 
There is evidence indicating that Aβ exhibits extremely high affinity binding to 
α7-nAChR (Wang et al., 2000b; Wang et al., 2000a) and modulates α7-nAChR 
function (Liu et al., 2001; Pettit et al., 2001; Wu et al., 2004a; Liu et al., 2009). In 
AD patients and in animal models, there are significantly higher levels of nAChR 
α7 subunit expression (Hellstrom-Lindahl et al., 1999; Dineley et al., 2002b; 
Hellstrom-Lindahl et al., 2004b; Hellstrom-Lindahl et al., 2004a; Jones et al., 
2006; Counts et al., 2007; Ikonomovic et al., 2009). It has been reported that 
animals with gain-of-function mutations in their α7-nAChR are highly susceptible 
to epileptic seizures (Broide et al., 2002). Furthermore, chronic exposure to Aβ 
up-regulates α7-nAChR expression in glial cells (Xiu et al., 2005; Yu et al., 2005). 
These lines of evidence raise a possibility that Aβ up-regulates α7-nAChR 
function, which may be an important mechanism in epileptogenesis in AD 
patients. In addition, it has been well established that acute exposure to Aβ 
suppresses α7-nAChR function in a variety of preparations (Liu et al., 2001; Pettit 
et al., 2001; Wu et al., 2004a; Liu et al., 2009), which may be related to α7 
nAChR up-regulation (Govind et al., 2009). Moreover, synaptic impairment and 
learning and memory deficits in a hAPPα7-/- mouse model are prevented by 
   
57
nAChR α7 subunit gene deletion (Dziewczapolski et al., 2009). Given that Aβ 
potently modulates α7-nAChR function (Liu et al., 2001; Pettit et al., 2001; Grassi 
et al., 2003; Wu et al., 2004a; Lamb et al., 2005; Spencer et al., 2006; Liu et al., 
2009), that α7-nAChR expression is significantly enhanced in both AD patients 
and animal models (Hellstrom-Lindahl et al., 1999; Dineley et al., 2002b; 
Hellstrom-Lindahl et al., 2004b; Hellstrom-Lindahl et al., 2004a; Jones et al., 
2006; Counts et al., 2007; Ikonomovic et al., 2009), and that α7-nAChR play an 
important role in regulating neuronal excitability (Dani, 2000; Sher et al., 2004; 
McKay et al., 2007), it is reasonable that α7-nAChR may contribute to Aβ-
induced neural hyperexcitation. In this project, we tested our hypothesis by using 
electrophysiological recordings from primary cultured hippocampal neurons and 
hippocampal slices from rats and WT/α7 KO mice. 
 
3.2 Materials and methods 
 
3.2.1 Primary cell culture 
The protocol for preparation of neuronal cultures from rodents was approved by 
the Institutional Animal Care and Use Committee of the Barrow Neurological 
Institute and St. Joseph's Hospital and Medical Center. Primary neuronal cultures 
were prepared from the postnatal wistar rat or C57BL/2 mice (WT or nAChR α7 
subunit KO) pups (1-3 d old), whose hippocampus containing the CA1 and CA3 
region was isolated after sacrifice and brain removal by dissection under a 
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stereological microscope. The cells were dissociated and maintained in culture in 
Neurobasal medium supplemented with 0.5% (w/v) L-glutamine and 2% B27 
serum-free supplement but without antibiotics. Cells were grown in a 5% CO2 
incubator at 37 °C. 
 
3.2.2 SH-SY5Y cell culture  
Human neuroblastoma cells (SH-SY5Y) were maintained in culture flasks in 
medium containing 50% minimal essential medium and 50% F-12 medium, 10% 
fetal bovine serum, 1% L-glutamine, and 1% penicillin/streptomycin antibiotic 
and grown in a 5% CO2 incubator at 37 °C. 
 
3.2.3 Differentiated SH-SY5Y cell  
Cells were harvested from flasks and plated in 48-well polystyrene plates 
(Corning Glass, Corning, NY) with 3 × 105 cells per 1 ml of medium per dish. 
The cells were differentiated by adding 10 μM retinoic acid to each dish and 
incubating at 37 °C for 4 days. After 4 days, the medium was exchanged with 1 
ml of serum-free media, followed by the addition of 100 nM fibril form of Aβ. 
100 nM Aβ scrambled was added into the medium of control cultures. Aβ and 
medium were changed daily until the day of experiments. 
 
3.2.4 Electrophysiology 
The standard external solution contained 140 mM NaCl, 3 mM KCl, 2 mM 
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MgCl2, 2 mM CaCl2, 10 mM d-glucose, 10 mM HEPES, adjusted to pH 7.4 with 
Tris base. The internal solution for current-clamp recordings to measure intrinsic 
excitability contained 130 mM KMeSO4, 10 mM KCl, 10 mM HEPES/K-HEPES, 
2 mM MgSO4, 0.5 mM EGTA and 3 mM ATP; the pH was adjusted to 7.3 with 
KOH. For miniature EPSC (mEPSC) recordings, 0.3 µM TTX, 50 µM picrotoxin, 
and 50 µM APV were added into external solution. For whole-cell recordings of 
ligand-gated ion channels and miniature EPSC (mEPSC) recordings, the internal 
solution contains the following: 140 mM potassium gluconate, 5 mM KCl, 10 
mM HEPES, 0.2 mM EGTA, 2 mM MgCl2, 4 mM MgATP, 0.3 mM Na2GTP 
and 10 mM Na2-phosphocreatine (pH 7.3 with KOH). Data were acquired by 
Axonpatch 200B amplifier at 2 kHz with pClamp 9.2 software (Molecular 
Devices, Sunnyvale, CA) and analyzed with clampfit 9.2 software (Molecular 
Devices, Sunnyvale, CA) and Mini Analysis software (Synaptosoft, Decatur, GA).  
 
3.2.5 Drugs, Aβ preparation, and Aβ treatment 
Drugs used in this study are (-) nicotine, methyllycaconitine (MLA), dihydro-β-
erythroidine (DHβE) (Sigma, St. Louis, MO), brefeldin A (Calbiochem, San 
Diego, CA), scramble Aβ1-42, and Aβ1-42 (rPeptide, Athens, GA). Aβ1-42 
peptides were dissolved in 1, 1,1,3,3,3-hexafluoro-2-propanol (HFIP) at a 
concentration of 1 mg/mL in 250 μL aliquots, air dried and stored at –20 °C. 
Aliquots were resuspended in dimethyl-sulfoxide (DMSO) and further diluted in 
phosphate buffered saline (PBS), pH 7.4, to a final concentration of 70 μM and 
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incubated at 37 °C without shaking. Oligomeric aggregates of Aβ1-42 were 
obtained after incubation for 6 h. For fibril formation, Aβ1-42 was incubated at 37 
°C for at least 96 h for Aβ1-42. Both oligomeric and fibrillar forms were verified 
by AFM before added into culture medium. Primary cultured neurons were 
maintained at 37 °C in a humidified atmosphere of 5% CO2/95% air for 10 days 
before Aβ1-42 treatments. Aβ1-42 treatment was performed by renewing Aβ1-42-
containing culture medium (100 nM) daily for 3-10 days. The same renewal 
procedure with medium containing scramble Aβ1-42 was performed as a control.  
 
3.2.6 Immunostaining 
Cells from hippocampal neuronal cultures (14–21 d in vitro) were injected with 
biocytin (5 mg/ml, included in the intracellular solution) for in their 35 mm 
culture dishes.  After recordings, cells were fixed in 4% paraformaldehyde for 10 
min and washed with PBS 3 times 5 min at room temperature. Then a PBS-based 
blocking solution containing 5% normal goat serum and 0.3% Triton X-100 was 
then applied for 1 h. After incubations at 4°C overnight with the primary goat 
anti-neurogranin antibody (1:100 dilution; Santa Cruz Biotechnology, Santa Cruz, 
CA), the cultures were then washed with PBS three times for 5 min. Thereafter, 
Avidin AF488 and the neurogranin secondary antibody Alexa 555-conjugated 
anti-goat were applied in the blocking solution for 2 h at room temperature (all 
used at 1:1000 dilutions; all from Invitrogen, Carlsbad, CA). The cultures were 
then finally washed three times for 5 min with PBS. 
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3.2.7 Immunoprecipitation of α7-nAChR 
To precipitate α7 receptors from the surface of primary cultures, we used a 
protocol modified from Charpantier et al. (Missbach et al., 1999; Charpantier et 
al., 2005). Primary cultured cells were incubated in media with or in the absence 
of 10 µM free (non-biotinylated) α-BT 30 min in the culture incubator. Thereafter 
300 nM biotinylated α-BT was added into the medium for 45 min. Cells were 
then washed three times with PBS and lysed as described above. Streptavidin-
agarose beads were added to precipitate surface AChRs. Total nAChR α7 
subunits were precipitated by adding biotinylated 300 nM α-BT to cell lysates, 
followed by streptavidin-agarose beads to harvest total α7 nAChR. Insoluble 
material was pelleted with centrifugation at 14,000 x g, and then the supernatants 
from samples were transferred to new tubes. The BCA protein assay (Pierce, 
Rockford, IL) was used to determine protein concentration. Samples were 
separated by SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad, 
Hercules, CA) and immunoblotted with a goat anti-α7 subunit antibody (1:100; 
Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C. After membranes 
were washed, anti-goat IgG, HRP-linked antibody secondary antibody (Santa 
Cruz Biotechnology, Santa Cruz, CA) was added and incubated for 1 h at room 
temperature. α7 subunits were then visualized by enhanced chemiluminescence 
kit (GE Healthcare BioSciences, Piscataway, NJ) and quantified using ImageJ 
(Rasband, 2009). 
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3.2.8 Quantitative real-time PCR 
Total RNA from primary neuronal cultures was extracted using column 
purification (Qiagen, Valencia, CA). First-strand cDNA was generated with 
random primers using iScript cDNA synthesis kits (BioRad, Hercules, CA). Real-
time analysis was performed on a  BioRad ICycler system (BioRad, Hercules, CA) 
using the following conditions: an initial denaturation for 10 min at 95°C, 
followed by 40 cycles of 15 s denaturation at 95 °C, 30 s annealing at 60°C and 1 
min extension at 72°C. Analysis was performed according to the ∆∆Ct method 
using GAPDH as the housekeeping gene. The primer sequences are: ACHA7, 5’-
TTGATGCCACGTTCCACACCAATG-3’ and 5’-
AGGGAACCAGCGAACGTCAATGTA-3’; ACHB2, 5’-
ACAATGCTGACGGCATGTACGA and TGCTGGTCAAATGGGAAGTGCT-
3’; and GAPDH, 5’-TGACTCTACCCACGGCAAGTTCAA-3’ and 5’-
ACGACATACTCAGCACCAGCATCA-3’. 
 
3.2.9 Calcium imaging 
For calcium imaging, hippocampal neurons were plated at a density of 4.5-
5.0X104 per cm2 on coverslips. Neurons were incubated with 2 M fura-2-AM 
(Molecular Probes) for 30 min at room temperature in artificial cerebrospinal 
fluid (ACSF: 140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM 
HEPES, 25 mM D-glucose). Cells were then washed in ACSF to remove excess 
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Fura-2 AM and incubated in ACSF for another 30 minutes to equilibrate. The 
cover slip with cells loaded with Fura-2 AM was then mounted in a perfusion 
chamber and placed on an inverted microscope (MS-508D, ALA).  
Baseline [Ca2+] was obtained over 1 minute prior to the initiation of stimulus that 
was maintained during the imaging. Stimulation was initiated by perfusion at 2 
ml/minute to a static bath of the indicated compounds. Fura-2 AM was 
successively excited by a xenon light source at 340 nm and 380 nm by means of 
two narrow beam band-pass filters selected by a computer-controlled filter wheel. 
The emitted fluorescence was filtered through a 520 nm filter, captured with an 
intensified CCD camera (Coolsnap fx, Roper Scientific), and analyzed with 
Imaging Work Bench software 5.0 (INDEC BioSystems, Santa Clara, CA). Data 
from interested regions were displayed in real-time and presented as 
representative traces averaged from at least 10 cells per experiment. Responses to 
treatments were quantified by determining the difference between the average 
subtracted 340/380 nM calcium signal ratios for the period of time of maximal 
response during the drug exposure and the average ratios for 30 seconds prior to 
exposure. Changes in subtracted 340/380 nM calcium signal ratios are presented 
as mean ± standard error of the mean (SEM) from three or more independent 
experiments with ≥10 cells per experiment.  
 
3.2.10 Lactate dehydrogenase (LDH) release assay 
Samples were measured following the protocol from the manufacturer (Sigma-
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Aldrich, St Louis, MO). As described previously (Zameer et al., 2008), aliquots 
(50 μL) of the media from each well were transferred to a 96-well plate. The 
remaining media was removed, the supplied lysis buffer was added, and the plates 
were incubated at 37 ºC for 1 h. The supplied buffer and substrate were then 
added to both the supernatant and lysed cell samples as described by the 
manufacturer. The plates were incubated in the dark at room temperature for 30 
min. The reaction was stopped and the absorbance was measured by substracting 
OD650 from OD490 using a plate reader (BioRad, Hercules, CA). The percentage 
of LDH release was calculated by dividing the LDH activity in culture media by 
the total LDH value. The data are reported as percentage of control value obtained 
from three independent experiments. 
 
3.2.11 Data Analysis and Statistics 
Data were given as mean ± SEM with numbers of samples analyzed (n). A 
probability level of p<0.05 was considered to be statistically significant. 
Significant differences were determined using the two-tailed Student’s t test, or 
one-way ANOVA as appropriate. 
 
3.3 Results 
 
3.3.1 Possible targets to mediate Aβ-induced neuronal hyperexcitation  
Neuronal excitability is determined by the balance of inward and outward ionic 
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conductances and by the balance of excitatory and inhibitory synaptic inputs. We 
performed experiments to determine the possible targets that mediated Aβ-
induced neuronal hyperexcitation. We compared Na+ and K+ channel currents and 
glutamate-, GABA- or ACh-induced currents between neurons treated with 100 
nM fibrillar or scrambled Aβ. The results demonstrated that only chronic Aβ 
exposure enhanced ACh-induced currents, and no other channels or receptors 
were affected (Table 3.1). 
 
 
      Aβ scramble  Aβ fibril  n 
 
INa (-20mV)       2476.5 +/- 226.7 3023.1 +/- 583.2  6 
IKa (A-type, +40 mV)   2317.5 +/- 339.1 2058.2 +/- 293.4 7 
IKd (Slow-Decay, +40 mV) 1821.6 +/- 136.7 1592.0 +/- 194.9 9 
GABA (0.1 mM)  1350.6 +/- 126.5 1255.7 +/- 150.1 9 
AMPA (0.1 mM)  1125.8 +/- 128.1 1277.3 +/- 101.2 10 
NMDA (0.1 mM)  955.2 +/- 105.8 1025.6 +/- 167.8 10 
ACh (1 mM)   123.3 +/- 20.3  547.2 +/- 68.7** 11 
 
**p<0.01, two tailed student t-test  
 
Table 3.1 Effects of Aβ on cell passive properties and VGICs and LGICs  
Cm: membrane capacitance, Rin: input resistance. Each channel group was 
collected from 5-11 cells tested. ** means p< 0.01 compared to control. 
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N/A: means no detectable current response. 
 
3.3.2 Aβ selectively up-regulates α7-nAChR function 
Utilizing AFM, we are able to verify the aggregation morphology of Aβ 
(monomer (Mon), oligomer (Oli), fibril (Fib); Figure 12 A a-d) before samples 
were added into culture medium. These different forms of Aβ at 100 nM were 
used to treat hippocampal neurons. After 4 days of treatment, α7-
nAChR/GABAR/AMPAR/NMDAR mediated currents in presumed pyramidal 
neurons were recorded by application of choline (10 mM), GABA (0.1 mM), 
AMPA (0.1 mM) or NMDA (0.1 mM) to presumed pyramidal neurons. 
Significant potentiation of α7-nAChR-mediated currents was observed after 4 
days exposure to 100 nM Aβ oligomer or fibril but not monomer, when compared 
to scrambled Aβ scramble (Current densities: Oli 15.83 ± 2.31, n=21; Fib 20.82 ± 
2.12, n=26; Scr 9.81 ± 1.37, n=22; Mon 10.39 ± 1.51 pA/pF, n=14; Oli Vs Scr 
p<0.01, Fib Vs Scr p<0.01, t-test;  Figure 12 B, C). To investigate whether or not 
this up-regulation of α7-nAChR function is a specific event, we compared α7-
nAChR-mediated currents to those mediated by other ligand-gated ion channels 
(LGICs); i.e., GABAR, AMPAR, and NMDAR, after 4 days of exposure to 
different Aβ forms. Interestingly, we found that whole-cells currents mediated by 
GABAR, AMPAR or NMDAR remain at the same level after treatment with 
different forms of Aβ. These results indicate that Aβ large aggregates selectively 
up-regulate α7-nAChR function but not other LGICs. 
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Figure 12 Specific up-regulation of α7-nAChR function by Aβ. 
A: Typical AFM images of scrambled Aβ (Scr; a) or of Aβ at 100 nM in 
monomeric (Mon; b), oligomeric (Oli; c), or fibril (Fib, d) forms. B: Typical 
whole-ell current traces showing that 4 days of treatment with oligomeric, and 
especially fibrillar, Aβ up-regulates function of α7-nAChR but not other LGICs. 
C: Calculated densities for currents induced by application of choline (10 mM), 
GABA (0.1 mM), AMPA (0.1 mM) or NMDA (0.1 mM) in presumed pyramidal 
neurons. Significant potentiation of α7-nAChR mediated currents was observed 
after 4 days exposure to Aβ oligomer or fibril but not monomer, when compared 
to scrambled Aβ (Current densities: Oli 15.83 ± 2.31, n=21; Fib 20.82 ± 2.12, 
n=26; Scr 9.81 ± 1.37, n=22; Mon 10.39 ± 1.51 pA/pF, n=14; Oli Vs Scr p<0.01, 
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Fib Vs Scr p<0.01, t-test). Current densities for GABAR, AMPAR and NMDAR 
remain the same level after treatment with different forms of Aβ.  
 
Based on the above data, Aβ large aggregates, especially fibril (Current densities: 
Fib Vs. Oli, p<0.05, t-test) seem to specifically and substantially up-regulate α7-
nAChR function.  
 
We did further experiments to confirm α7-nAChR up-regulation and to determine 
the bases for that change in pyramidal neurons. We microinjected biocytin into 
presumed pyramidal neurons after recording α7-nAChR mediated currents (Fig 13 
A). Thereafter, immunostaining with neurogranin was used to confirm that the 
recorded cell was a pyramidal neuron (Fig. 13A).  Other studies indicated that α7-
nAChR function was up-regulated in pyramidal neurons only after fibrillar Aβ 
treatment (Figure 13 B and C). To determine the bases for these effects, we 
examined surface and total nAChR α7 subunit levels after 4 days of Aβ Fib 
treatment by using biontinylated BT with streptavidin to pull down α7-nAChR 
and/or α7 subunits from primary cultured hippocampus neurons followed by 
western analysis using anti-nAChR α7 subunit antibody probing. Immunoblotting 
data indicated a significant elevation of surface α7 subunit protein and presumed 
α7-nAChR after treatment with fibril Aβ, but the total α7 subunit protein level 
remained comparable to that in controls treated with scrambled Aβ (Figure 13 D 
and E; Fib Vs Scr p<0.01, t-test). Together, these results show that fibrillar Aβ 
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exposure increases surface α7-nAChR without changing total α7 subunit protein 
levels. 
 
 
Figure 13 Aβ up-regulates α7-nAChR expression and function in cultured 
hippocampal pyramidal neurons.  
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A: Cultured hippocampal pyramidal neurons microinjected with biocytin after 
recording can be identified, and neurogranin immunostaining can be used to 
confirm identity as pyramidal neurons.  a and b, the same cultured hippocampal 
pyramidal neuron treated with scrambled Aβ. c and d, the same cultured 
hippocampal pyramidal neuron treated with fibrillar Aβ. B: Typical traces of 10 
mM choline-induced current responses in cultured hippocampal pyramidal 
neurons treated with scrambled Aβ (a) or fibrillar Aβ (b). The period of exposure 
to choline is presented as horizontal bars above the traces. The holding potential 
was -60 mV. C: Bar graph summarizes peak whole-cell current densities produced 
during acute application of 10 mM choline to pyramidal neurons treated with 
scrambled or fibrillar Aβ (fibril 22.68 ± 3.51, n=17; scrambled 10.62 ± 1.39, n=15. 
p<0.01, t-test). D: Immunoprecipitation-western blot experiments showed that 
chronic exposure to fibrillar Aβ increased apparent α7-nAChR expression on the 
neuronal surface but not the total amount of α7 subunit protein. E: Bar graph 
summarizes α7-nAChR expression levels before and after chronic exposure to 
scrambled or fibrillar Aβ or Aβ. Data were normalized to α7-nAChR expression 
in scrambled Aβ-treated controls (fibril Vs scramble; p<0.01, t-test). 
 
To confirm that the up-regulation of α7-nAChR function was induced by fibrillar 
Aβ and to evaluate the impact on calcium influx, we utilized calcium imaging to 
define calcium influx in cultured hippocampus neurons after chronic exposure to 
scrambled or fibrillar Aβ. Neurons were seeded on coverslips and imaged after 
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treatment with Aβ for 10 days. As shown in figure 14, after Aβ fibril chronic 
treatment, choline 10 mM application induced more a dramatic increase of 
calcium signal when compared to neurons treated with scrambled Aβ (Figure 14; 
fibril 228 ± 23% Vs. scramble 132 ± 11%; p<0.01, t-test). Moreover, choline-
induced calcium influx can be blocked by the selective α7-nAChR antagonist, 
methyllycaconitine (MLA; 10 nM). These data suggest that chronic treatment with 
fibrillar Aβ increases calcium influx through α7-nAChR in presumed cultured 
hippocampus pyramidal neurons. 
 
 
 
Figure 14 Chronic treatment with Aβ fibrils increases calcium influx through 
α7-nAChR in cultured hippocampus neurons.  
Cultured hippocampus neurons were chronically treated with Aβ fibril for 10 days. 
Application of 10 mM choline induced a dramatic increase in calcium influx in 
cultured hippocampus neurons treated with Aβ fibrils relative to effects on 
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neurons treated with control, scrambled Aβ treated (fibril 228 ± 23% Vs. 
scrambled 132 ± 11%. p<0.01, t-test). Choline induced-calcium influx can be 
blocked by the selective α7-nAChR antagonist MLA (10 nM). 
 
3.3.3 Mechanisms of Aβ-induced up-regulation α7-nAChR  
To investigate underlying mechanisms of Aβ-induced up-regulation of α7-nAChR, 
we first examined the time course of Aβ’s effects on α7-nAChR function in 
pyramidal neurons. As shown in Figure 15 A and B, the current density for α7-
nAChR-mediated responses increased after at least 4 days of treatment with Aβ 
fibrils.  To test whether or not this upregulation of α7-nAChR function is due to an 
increase in nAChR α7 subunit gene expression, we did gel- and RT-PCR-based 
mRNA quantifications. As shown in Figure 4E, using real-time PCR, there was no 
increase in nAChR α7 subunit mRNA expression relative to GAPDH mRNA 
(Figure 15 C). No increase was observed in nAChR β2 subunit mRNA level. Thus, 
up-regulation of functional α7-nAChR expression seems to involve a post-
translational trafficking mechanism.  
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Figure 15 Aβ up-regulates α7-nAChR in cultured hippocampal neurons. 
A: Representative traces of 10 mM choline-induced current responses in cultured 
hippocampal neurons treated with fibrillar Aβ for the indicated periods. B: Bar 
graph summarizes the 10 mM choline-induced peak current density from neurons 
treated with Aβ fibril for the indicated periods. C: Real-time RT-PCR showed that 
Aβ fibril did not alter α7 subunit mRNA expression level. Levels of nAChR 
mRNA were normalized to scrambled Aβ-treated neurons. Data in each group 
were internally normalized to GAPDH mRNA expression. 
 
To test this hypothesis, we then used brefeldin-A (BFA) to treat the cultures prior 
to and during Aβ fibril exposure.  BFA has been used to inhibit transport of 
   
74
proteins from the endoplasmic reticulum (ER) to the Golgi. Treating the cultures 
with BFA 10 µg/ml completely abolished the Aβ fibril exposure-induced increase 
of α7-nAChR function and surface α7-nAChR expression (Figure 16 A-D), which 
suggests that BFA prevented the increase of surface α7-nAChR by inhibiting the 
transport from the ER to the Golgi. No decrease of surface α7-nAChR expression 
was seen in control cultures treated with BFA, indicating that basal turnover of 
receptor is low or negligible during the course of the experiments (Figure 16 C 
and D). 
 
 
 
Figure 16 BFA prevented the increase of surface α7-nAChR induced by Aβ 
fibril exposure. 
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A: Typical whole-cell current response traces for functional activation of α7-
nAChR by 10 mM choline shows that treating hippocampal pyramidal neuron 
cultures with BFA 10 µg/ml inhibited Aβ fibril exposure-induced increases in α7-
nAChR function. B: Bar graph summaries the results of measurements of current 
density induced by 10 mM choline in cultured hippocampal neurons treated as 
indicated. BFA 10 µg/ml exposure inhibits the Aβ fibril exposure-induced 
increase in α7-nAChR function (fibril 23.59 ± 3.23, n=8; fibril + BFA 12.16 ± 
2.13, n=11. p<0.01, t-test). C: Treating the cultures with BFA 10 µg/ml inhibited 
Aβ fibril exposure-induced increases in surface α7-nAChR expression. D: Bar 
graph summaries the effects on surface α7-nAChR expression vy cultured 
hippocampal neurons treated as indicated. BFA 10 µg/ml exposure inhibited Aβ 
fibril exposure induced increase of α7-nAChR function (fibril 183.22 ± 32.16%, 
n=8; fibril + BFA 131.63 ± 23.28%, n=4, p<0.01, t-test). 
 
3.3.4 Aβ treatment enhances α7-nAChR-mediated action potential firings 
To test the consequences of α7-nAChR up-regulation on neuronal activity after 
Aβ fibril treatment, we used agonists to activate α7-nAChR and recorded 
pyramidal neurons’ membrane potentials and firing activities under current clamp 
mode (Figure 17 A-C). Results showed that after Aβ fibril treatment, pyramidal 
neurons displayed a significant increase in membrane potential changes and action 
potential (AP) firing activated by choline, a selective agonist for α7-nAChR, or by 
nicotine relative to responses in control neurons treated with scrambled Aβ (MP 
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changes: Aβ fibril: 16.21 ± 1.56 mV, n = 8; Aβ scrambled: 10.22 ± 1.06 mV, n = 8; 
p < 0.01; AP frequency: Aβ fibril: 15.73 ± 1.36, n = 8; Aβ scrambled: 3.91 ± 0.66 
mV, n = 8; p < 0.01). By contrast, non-α7-nAChR agonists RJR 2403 and cytisine 
failed to induce enhanced action potential firing or changes in resting membrane 
potential. In addition, effects of α7-nAChR agonists on resting membrane 
potential elevation and increased action potential firing can be completely blocked 
by a selective α7-nAChR antagonist, methyllycaconitine (MLA), but not by a non-
α7-nAChR antagonist mecamylamine (MEC) or a β2*-nAChR-selective 
antagonist, dihyrdo-β-erythrodine (DHβE). These findings suggest a specific 
potentiation of activation effects mediated by α7-nAChR after treatment with Aβ 
fibrils. 
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Figure 17 Chronic Aβ treatment enhances α7-nAChR-mediated action 
potential firing. 
Experiments were performed in current-clamp recording mode. A: Activation of 
α7-nAChR in control, cultured hippocampal neurons by nicotine or choline but 
not by cytisine or the α4β2-nAChR-selective agonist, RJR-2403, induces some 
change membrane potential due to action potential firing. B: Enhanced excitation 
of cultured hippocampal neurons activated by α7-nAChR agonists nicotine and 
choline after chronic Aβ treatment is evident based on larger deviations in 
membrane potential changes during action potentials and a higher frwquency of 
action potential firing. C: Nicotine- (or choline-; not shown) induced 
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hyperexcitation is selected abolished by a selective α7-nAChR MLA antagonist, 
but not by non-α7-nAChR antagonists. 
 
3.3.5 Chronic Aβ treatment up-regulates α7-nAChR in SH-SY5Y cell line 
To corroborate and confirm the chronic Aβ treatment induced up-regulation of α7-
nAChR, we utilized differentiated SH-SY5Y cells as a cell line model. When SH-
SY5Y cells were differentiated into cholinergic cells as shown in figure 18 Ab and 
Bb, these cells express respectable amounts of both α7- and non-α7-nAChR 
(α3β4*-nAChR) (Figure 19 A). ACh induces current through both receptor types, 
and the responses remaining in the presence of mecamylamine are likely due to 
α7-nAChR because they have fast macroscopic kinetics.  The early, transient, 
peak current responses to ACh or choline also likely are due to α7-nAChR 
function, because they are eliminated in the presence of MLA.   
 
We then treated these cells with scrambled or fibrillar Aβ for 4 days, and then we 
determined α7-nAChR functional levels.  As shown in Figure 20, 4 days of 
exposure to fibrillar Aβ selectively up-regulates α7-nAChR function when 
compared to scrambled Aβ-treated controls. That is responses to ACh or choline 
are increased, as are responses to ACh in the presence of mecamylamine, but 
responses to ACh in the presence of MLA and mediated by non-α7-nAChRF are 
not increase. Interestingly, 4 days of exposure of differentiated SH-SY5Y cells to 
Aβ fibrils produces a significant reduction in cell viability (Figure 21).  
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Together, these data suggest Aβ selectively up-regulates α7-nAChR function in 
differentiated cholinergic SY5Y cells. The up-regulated α7-nAChR function 
occurs with the loss of SH-SY5Y cell viability. These results are consistent with 
the findings in cultured hippocampal neurons, indicating the up-regulation of α7-
nAChR function by chronic Aβ exposure is reproducible in different cells. 
 
 
 
Figure 18 Undifferentiated and differentiated SH-SY5Y cells. 
A: Undifferentiated (a) and differentiated (b) SH-SY5Y cells at 4X. 
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Scale bar = 50 µm. B: Undifferentiated (a) and differentiated (b) SH-SY5Y cells 
at 20X (scale bar = 10 μm. 
 
 
 
Figure 19 Differentiated SH-SY5Y cells express functional α7-nAChR and 
non-α7-nAChR. 
A: Sample traces are shown for differentiated SH-SY5Y cell responses to the 
indicated drugs at the specified concentrations (ACh, choline - Ch, ACh + Mec, 
ACh +MLA). B: Bar graph summarizes the currents induced by drug application. 
A 
B 
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Figure 20 Chronic exposure to Aβ fibril induced up-regulation of α7-nAChR.  
A: Sample traces from differentiated SH-SY5Y cells treated for 4 days at 100 nM 
with scrambled (upper traces) or fibrillar (lower traces) Aβ and responding to the 
indicated drugs at the specified concentrations.  Note calibration bars.  B: Bar 
graph summarizing the data showing that normalized current amplitudes for 
responses to the indicated agents are higher than in scrambled Aβ-treated controls 
for cells exposed for 4 days to 100 nM Aβ fibrils, especially with regard to 
responses to ACh, choline, and ACh in the presence of MEC, but not significantly 
for responses to ACh + MLA, indicating selective up-regulation of α7-nAChR 
function (** p<0.01, t-test). 
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Figure 21 Chronic exposure to Aβ fibril causes reduced cell viability. 
Chronic exposure to Aβ fibril causes a significant reduction in SH-SY5Y cell 
viability, as assessed by LDH release, starting from Day 4 (** p<0.01, t-test). 
 
3.4 Discussion 
 
Much evidence has indicated that Aβ affects neuronal function and excitability 
(Palop et al., 2007; Wang et al., 2009a) but the results are often contradictory 
(Klyubin et al., 2004; Puzzo et al., 2008). This conflict is likely caused by the 
wide range of Aβ experimental protocols used. For instance, low Aβ 
concentrations enhance, but high Aβ concentrations depress hippocampal 
** 
** 
100 nM Aβ treatment induced cytotoxicity 
** 
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synaptic plasticity (Puzzo et al., 2008); oligomeric Aβ modulates neuronal 
function more dramatically than monomeric Aβ (Shankar et al., 2008); acute Aβ 
depresses, but chronic Aβ up-regulates, α7-nAChR function (Liu et al., 2001; Wu 
et al., 2004b; Xiu et al., 2005; Yu et al., 2005; Liu et al., 2009). Therefore, it is 
very important to optimize Aβ experimental protocols. In addition, the 
characterization of Aβ concentrations and forms has clinical relevance: low 
nanomolar Aβ concentrations are relevant to pathological levels in AD; 
oligomeric Aβ forms show more toxic effects (Hardy and Selkoe, 2002). In our 
experiments, we utilized the AFM to optimize standards for preparation of specific 
forms of Aβ and to determine the aggregation form of Aβ present when 
characterizing Aβ-induced neuronal hyperexcitation. Based on our data, we found 
that chronic exposure to Aβ, particularly to fibrillar Aβ up-regulated α7-nAChR 
surface expression and function and increased neuronal excitability. The Aβ 
concentration used to induce neuronal hyperexcitation was 100 nM, which is at the 
high end of the pathological level of AD ranges (1-100 nM). 
 
Accumulating evidence indicates that Aβ exhibits quite broad effects on a variety 
of receptors/channels under in vitro experimental conditions. However, most 
acute effects of Aβ on these receptors/channels either on astrocytes (Abramov et 
al., 2004; Abramov and Duchen, 2005) or on neurons require much higher 
concentrations of Aβ (micro-molar level) (Casley et al., 2009) than those seen in 
AD patient brain (1-100 nM) (Cirrito and Holtzman, 2003). The α7-nAChR is a 
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selective target for Aβ since it is highly sensitive to Aβ block (Liu et al., 2001; 
Pettit et al., 2001; Liu et al., 2009). These findings suggested that Aβ, at 
pathological concentrations, might specifically acts on α7-nAChR to affect 
neuronal excitability.  By comparing the effects of chronic Aβ on a variety of ion 
channel function, we found that enhancing ACh-induced current is a specific 
event under our experimental conditions. After exposure to Aβ, the activation of 
α7-nAChR excites hippocampal neurons, which can be abolished by a selective 
α7-nAChR antagonist.  
 
In the recent decade, several groups have reported direct and functionally-relevant  
interactions of Aβ with α7-nAChR (Wang et al., 2000b; Wang et al., 2000a; Liu 
et al., 2001; Pettit et al., 2001). Thereafter, other groups, including ours, reported 
the effects of Aβ on α7-nAChR (Wu et al., 2004a; Liu et al., 2009). Most in vitro 
studies show an inhibitory effect of acute application of Aβ on neural model 
preparations including native α7-nAChR-expressing cells in culture, brain slices, 
and cells transfected to express α7-nAChR (Liu et al., 2001; Pettit et al., 2001; 
Grassi et al., 2003; Wu et al., 2004a; Lamb et al., 2005; Spencer et al., 2006; Liu 
et al., 2009). In addition, activation of α7-nAChR significantly enhances cognitive 
function (Levin and Rezvani, 2002). These findings suggest that in AD, 
impairment of α7-nAChR function by Aβ inhibition contributes to cholinergic 
signaling deficits and cognitive decline, and that enhancement of α7-nAChR 
function would be a therapeutic strategy in treatment of AD (Bencherif and 
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Schmitt, 2002; Buccafusco et al., 2005; D'Andrea and Nagele, 2006; Buckingham 
et al., 2009). However, more recent evidence has challenged this concept. For 
instance, some reports demonstrate an activating effect of Aβ on heterologously 
transfected α7-nAChR in oocytes (Dineley et al., 2002a) and native nAChR (Fu 
and Jhamandas, 2003). Furthermore, although Aβ inhibits α7-nAChR acutely, 
these receptors exhibit enhanced expression (mRNA and protein) in both AD 
patients and AD model animals (Hellstrom-Lindahl et al., 1999; Dineley et al., 
2002b; Hellstrom-Lindahl et al., 2004b; Hellstrom-Lindahl et al., 2004a; 
Teaktong et al., 2004; Chu et al., 2005; Jones et al., 2006; Counts et al., 2007), 
and functionally, α7-nAChR-mediated currents are at least comparable between 
APP transgenic and wild-type mice at adult ages (Spencer et al., 2006). The 
possible interpretation is that the inhibition of α7-nAChR by Aβ may trigger 
receptor up-regulation (Molinari et al., 1998).  These lines of evidence suggest 
that Aβ up-regulates α7-nAChR function, which may be an important mechanism 
in epileptogenesis in AD patients. In the current study, we discover that α7-
nAChR is up-regulated by chronic exposure to Aβ, which is mediated by post-
translational mechanisms in cultured hippocampal pyramidal neurons. The fact 
that up-regulation of surface α7-nAChR but total α7-nAChR level remain 
unchanged suggests increased protein trafficking and assembling. Gel-based RT-
PCR and Real-Time PCR both failed to detect increased mRNA synthesis, which 
also support the up-regulation of α7-nAChR is through post-translational 
mechanisms. BFA treatment blocked the up-regulation of surface α7-nAChR 
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without affect total α7-nAChR levels. This finding suggests that chronic Aβ 
treatment up-regulate surface α7-nAChR by increase protein trafficking from the 
ERs to Golgi. 
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Chapter 4 
ROLES OF α7-nAChR IN Aβ-INDUCED NEURONAL 
HYPEREXCITATION  
 
4.1 Introduction 
 
Accumulating lines of evidence demonstrate that in AD patients and model 
animals, Aβ and α7-nAChR express at an aberrantly high level, and neuronal 
circuits exhibit hyperexcitation (Hellstrom-Lindahl et al., 1999; Dineley et al., 
2002b; Jones et al., 2006; Spencer et al., 2006; Palop et al., 2007; Busche et al., 
2008; Westmark et al., 2008; Palop and Mucke, 2009a). In addition, mounting 
evidence suggests that α7-nAChR contribute to the modulation of neuronal 
excitability and the generation of epileptic seizures (Miner et al., 1986; Miner and 
Collins, 1989; Damaj et al., 1999; Ivy Carroll et al., 2007). These lines of 
evidence lead to a reasonable hypothesis that the up-regulation of α7-nAChR by 
Aβ may contribute to neural hyperexcitation.  
 
Accumulating evidence indicates that Aβ exhibits quite broad effects on a variety 
of receptors/channels under in vitro experimental conditions.  However, most 
acute effects of Aβ on these receptors/channels either on astrocytes (Abramov et 
al., 2004; Abramov and Duchen, 2005) or on neurons require much higher 
concentrations of Aβ (micro-molar level) (Casley et al., 2009) than those seen in 
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AD patient brain (low nano-molar level) (Cirrito and Holtzman, 2003). The α7-
nAChR is a specific target for Aβ since this receptor exhibits super-high affinity 
for Aβ binding (Wang et al., 2000b; Wang et al., 2000a), and functionally, it is 
highly sensitive to Aβ block (Liu et al., 2009). These findings, coupled with our 
results, have led to a hypothesis that Aβ, at pathological concentrations, might 
specifically acts on α7-nAChR to affect neuronal excitability. After we examined 
chronic effects of Aβ on various voltage-gated (Na+, K+ and Ca2+) and ligand-
gated ion channels (e.g., ionotropic glutamate receptors, GABAA receptor), we 
have found that Aβ selectively affect α7-nAChR function, which suggest that α7-
nAChR is a specific target to mediate Aβ’s effect under our experimental 
conditions (i.e. at Aβ concentrations that are observed in AD brain). 
 
α7-nAChR exhibit high Ca2+ permeability(Castro and Albuquerque, 1995), and 
activation of α7-nAChR increases intracellular calcium levels (Delbono et al., 
1997), which can increase neuronal excitability. It has been reported that chronic 
exposure  of cultured neurons to Aβ elevates intracellular Ca2+ levels, an effect 
which may be mediated through nAChR (Wu et al., 2009). To address this 
question, we have done two experiments: (1) comparing intracellular Ca2+ levels 
between Aβ treated and un-treated neurons using Fura-2 Ca2+ imaging (Wu et al., 
2006; Misaki et al., 2007), and (2) comparing neuronal excitability in Aβ treated 
hippocampal neurons prepared from α7-/- and WT mice. Results gained from 
above two experiments indicated that Aβ chronic treatment elevated intracellular 
   
89
Ca2+ concentration through α7-nAChR, which in turn caused the Aβ-induced 
increases of intrinsic excitability.  
 
It has been reported that Aβ acts on presynaptic α7-nAChR and elevates 
intracellular Ca2+ levels (Dougherty et al., 2003), which can promote 
neurotransmitter (mainly glutamate) release. Therefore, Aβ possibly induces 
neuronal hyperexcitation through this mechanism, especially if α7-nAChR has 
been up-regulated. To test this possibility, the frequency and amplitude of 
mEPSCs from cultured hippocampus pyramidal neurons were analyzed and 
compared between Aβ treated neurons prepared from α7-/- and WT mice. Our 
results suggested that Aβ-induced increase of mEPSCs frequency was mediated 
through a presynaptic mechanism.  
 
Using patch-clamp electrophysiological, pharmacological and molecular 
biological approaches, our findings demonstrate a profound role of α7-nAChR 
regulating neuronal hyperexcitation induced by pathologically-relevant 
concentrations of Aβ. α7-nAChR, could mediate Aβ-induced epilepsy or 
cognitive deficits in AD, and thus might be a target for early interventional 
therapies. 
 
4.2 Materials and methods 
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4.2.1 Primary cell culture 
The protocol for preparation of neuronal cultures from rodents was approved by 
the Institutional Animal Care and Use Committee of the Barrow Neurological 
Institute and St. Joseph's Hospital and Medical Center. Primary neuronal cultures 
were prepared as described previously (Alger et al., 1994; Shah et al., 2002; 
Filippov et al., 2006), with minor modifications. 1~3 day-old postnatal wistar rat 
or C57BL/2 mice [wild-type (WT) or nAChR α7 subunit knock-out (KO)] pups 
(1-3 d old) were sacrificed and hippocampus tissue containing the CA1 and CA3 
region was dissected under a stereological microscope. The cells were dissociated 
and maintained in culture in Neurobasal medium supplemented with 0.5% (w/v) 
L-glutamine and 2% B27 serum-free supplement but without antibiotics as 
described previously (Alger et al., 1994; Shah et al., 2002; Filippov et al., 2006). 
 
4.2.2 Electrophysiology 
The standard external solution contained 140 mM NaCl, 3 mM KCl, 2 mM 
MgCl2, 2 mM CaCl2, 10 mM d-glucose, 10 mM HEPES, adjusted to pH 7.4 with 
Tris base. Current-clamp recordings to measure intrinsic excitability were 
performed as described previously (Desai et al., 1999). Briefly, the internal 
solution contained 130 mM KMeSO4, 10 mM KCl, 10 mM HEPES/K-HEPES, 2 
mM MgSO4, 0.5 mM EGTA and 3 mM ATP; the pH was adjusted to 7.3 with 
KOH. For miniature EPSC (mEPSC) recordings, 0.3 µM TTX, 50 µM picrotoxin, 
and 50 µM APV were added into external solution. For whole-cell recordings of 
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ligand-gated ion channels and mEPSC recordings, the internal solution contains 
the following: 140 mM potassium gluconate, 5 mM KCl, 10 mM HEPES, 0.2 mM 
EGTA, 2 mM MgCl2, 4 mM MgATP, 0.3 mM Na2GTP and 10 mM Na2-
phosphocreatine (pH 7.3 with KOH). Data were acquired by Axonpatch 200B 
amplifier at 2 kHz with pClamp 9.2 software (Molecular Devices, Sunnyvale, CA) 
and analyzed with clampfit 9.2 software (Molecular Devices, Sunnyvale, CA) and 
Mini Analysis software (Synaptosoft, Decatur, GA).  
 
4.2.3 Drugs, Aβ preparation, and Aβ treatment 
Drugs used in this study are (-) nicotine, methyllycaconitine (MLA), dihydro-β-
erythroidine (DHβE) (Sigma, St. Louis, MO), brefeldin A (Calbiochem, San 
Diego, CA), scramble Aβ1-42, and Aβ1-42 (rPeptide, Athens, GA). Different 
forms of Aβ1-42 were prepared as previously described (Zameer et al., 2008). In 
brief, Aβ1-42 peptides were dissolved in 1, 1,1,3,3,3-hexafluoro-2-propanol 
(HFIP) at a concentration of 1 mg/mL in 250 μL aliquots, air dried and stored at –
20 °C. Aliquots were resuspended in dimethyl-sulfoxide (DMSO) and further 
diluted in phosphate buffered saline (PBS), pH 7.4, to a final concentration of 70 
μM and incubated at 37 °C without shaking. Oligomeric aggregates of Aβ1-42 
were obtained after incubation for 6 h. For fibril formation, Aβ1-42 was incubated 
at 37 °C for at least 96 h for Aβ. Both oligomeric and fibrillar forms were verified 
by AFM before added into culture medium. Primary cultured neurons were 
maintained at 37 °C in a humidified atmosphere of 5% CO2/95% air for 10 days 
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before Aβ treatments. Aβ treatment was performed by renewing Aβ-containing 
culture medium (100 nM) daily for 3-10 days. The same renewal procedure with 
medium containing scramble Aβ was performed as a control.  
 
4.2.4 Immunostaining 
Cells from hippocampal neuronal cultures (14–21 d in vitro) were injected with 
biocytin (5 mg/ml, included in the intracellular solution) for in their 35 mm 
culture dishes.  After recordings, cells were fixed in 4% paraformaldehyde for 10 
min and washed with PBS 3 times 5 min at room temperature. Then a PBS-based 
blocking solution containing 5% normal goat serum and 0.3% Triton X-100 was 
then applied for 1 h. After incubations at 4°C overnight with the primary goat 
anti-neurogranin antibody (1:100 dilution; Santa Cruz Biotechnology, Santa Cruz, 
CA), the cultures were then washed with PBS three times for 5 min. Thereafter, 
Avidin AF488 and the neurogranin secondary antibody Alexa 555-conjugated 
anti-goat were applied in the blocking solution for 2 h at room temperature (all 
used at 1:1000 dilutions; all from Invitrogen, Carlsbad, CA). The cultures were 
then finally washed three times for 5 min with PBS. 
 
4.2.5 LDH Release Assay 
Samples were measured following the protocol from the manufacturer (Sigma-
Aldrich, St Louis, MO). As described previously (Zameer et al., 2008), aliquots 
(50 μL) of the media from each well were transferred to a 96-well plate. The 
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remaining media was removed, the supplied lysis buffer was added, and the plates 
were incubated at 37 ºC for 1 h. The supplied buffer and substrate were then 
added to both the supernatant and lysed cell samples as described by the 
manufacturer. The plates were incubated in the dark at room temperature for 30 
min. The reaction was stopped and the absorbance was measured by substracting 
OD650 from OD490 using a plate reader (BioRad, Hercules, CA). The percentage 
of LDH release was calculated by dividing the LDH activity in culture media by 
the total LDH value. The data are reported as percentage of control value obtained 
from three independent experiments. 
 
4.2.6 Data Analysis and Statistics 
Data were given as mean ± SEM with numbers (n). A probability level of p<0.05 
was considered to be statistically significant. Significant differences were 
determined using the two-tailed Student’s t-test or one-way ANOVA as 
appropriate. 
 
4.3 Results 
 
4.3.1 Role of α7-nAChR in the induction of hyperexcitation 
We then asked if α7-nAChR play a role in the “induction” of Aβ-induced 
neuronal hyperexcitation by comparing cultured hippocampal neurons from WT 
or α7 KO mice, repeating our experiments of membrane excitability and 
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excitatory synaptic activity. α7-nAChR KO mice were genotyped by PCR, as 
shown in Figure 22. Figure 23 A shows the sample traces of spike activities 
induced by current injection from WT or KO pyramidal neurons treated with 
fibrillar or scrambled Aβ for 7 days.  With the absence of α7-nAChR, Aβ fibril 
exposure failed to induce the potentiation of spike activity (Figure 24 B, Aβ fibril 
treated WT: n = 10; KO: n = 12; t-test, p < 0.01) and MP changes recorded from 
cultured hippocampal pyramidal neurons (Figure 23 C; Aβ fibril treated WT: 
14.43 ± 1.25 mV, n = 10; KO: 9.43 ± 0.86 mV, n = 8; t-test, p < 0.01).  The spike 
activities and resting membrane potentials were not altered by α7 KO compared 
with WT controls (data not shown). Figure 24 shows that α7-nAChR KO 
prevented the increase of mEPSC frequency induced by Aβ fibril treatment 
(Figure 24 A and B; Aβ fibril treated WT: 5.53 ± 0.38 Hz, n = 8; KO: 4.38 ± 0.29 
Hz, n = 8; t-test, p < 0.01).   
 
 
 
Figure 22 Genotyping of α7-nAChR KO mice. 
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Genotype analyses demonstrated that nAChR α7 subunits are not expressed in 
nAChR α7 knockout (KO) mice, whereas AK (as a marker for the knockout) was 
absent in wild-type (WT) mice. Heterozygotic mice express both AK and nAChR 
α7 subunits. 
 
 
 
Figure 23 Deletion of α7-nAChR prevents chronic Aβ exposure-induced 
increases in intrinsic excitability. 
A: Typical traces show that genetic deletion of   α7-nAChR   prevented   the 
induction of neuronal hyperexcitation by 7 days exposure to 100 nM fibrillar Aβ 
seen in wild-type mice. B: Calculated input-output relationships for action 
potential spike activity as a function of current injected in cultured hippocampus 
neurons prepared from WT and α7 KO mice. Results showed that genetic deletion 
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of α7-nAChR prevented the increase of intrinsic excitability induced by chronic 
Aβ exposure (Aβ fibril treated WT: n = 10; KO: n = 12; t-test, p < 0.01). C: 
Genetic deletion of α7-nAChR prevented the increase in changes in MP induced 
by chronic Aβ exposure as seen in wild-type mice (Aβ fibril treated WT: 14.43 ± 
1.25 mV, n = 10; KO: 9.43 ± 0.86 mV, n = 8; t-test, p < 0.01).  
 
 
 
Figure 24 Genetic deletion of   α7-nAChR prevented the increase of synaptic 
activity induced by chronic Aβ exposure. 
A: Sample traces show that genetic deletion of α7-nAChR prevented 7 days 
fibrillar Aβ exposure-induced increases in mEPSCs recorded from cultured 
hippocampal pyramidal neurons. B: Chronic Aβ treatment increased mEPSCs 
frequency (b) but not amplitude (a) in hippocampal pyramidal neurons from wild-
type mice, but the effect is not present in α7-/- mice (Aβ fibril-treated WT: 5.53 ± 
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0.38 Hz, n = 8; KO: 4.38 ± 0.29 Hz, n = 8; t-test, p < 0.01). 
 
These data provide further evidence of specificity of α7-nAChR involvement in 
mediating the induction by Aβ of neuronal hyperexcitation. 
 
4.3.2 Role of α7-nAChR in the expression of hyperexcitation 
We hypothesized that α7-nAChR play a major role in the mediation of Aβ fibril-
induced potentiation of both membrane excitability and excitatory synaptic 
transmission. To test this hypothesis, we first examined whether pharmacological 
block of α7-nAChR eliminated the “expression” of murine hippocampal 
pyramidal neuronal hyperexcitation after chronic Aβ exposure. Pre-incubating 
neurons with MLA (10 nM) also abolished the potentiation of spike activities 
(Figure 25 A and B, Aβ fibril: n=8; pre-incubated with MLA: n = 11; t-test p < 
0.01) and MPs elevations induced by 7 days of Aβ fibril treatment (Figure 25 B 
and C, Aβ fibril: 14.82 ± 1.63 n=8; pre-incubated with MLA: 11.14 ± 0.98, n = 11; 
t-test, p < 0.01). However, no such effect was seen after preincubation of neurons 
with a selective β2-nAChR antagonist, DHβE (3 µM) (Figure 26 B and C, spike 
activity: pre-incubated with DHβE: n = 12, t-test, p > 0.05; MPs: pre-incubated 
with DHβE: 14.38 ± 0.86 mV, n = 12; t-test, p > 0.05). MLA pre-incubation 
prevented the Aβ-induced enhancement of mEPSC (Figure 26 A and B, Aβ fibril: 
6.73 ± 3.58 Hz, n=8; pre-incubated with MLA: 5.05 ± 0.33 Hz, n = 9; t-test, p < 
0.01), while DHβE failed to prevent this enhancement (Figure 26 A and B, pre-
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incubated with DHβE: 6.40 ± 0.45 Hz, n = 8; t-test, p < 0.01).   
 
Taken together, above results suggest that α7-nAChR play important roles in both 
induction and expression of neuronal hyperexcitation after chronic Aβ exposure. 
Enhancement of presynaptic α7-nAChR-mediated modulation of excitatory 
neurotransmission may contribute to Aβ-induced neuronal hyperexcitation.   
 
 
Figure 25 Pre-incubating neurons with MLA prevented chronic Aβ exposure-
induced increases in intrinsic excitability of hippocampal pyramidal neurons. 
A: Typical traces for spike production upon injection of a 90 pA current into 
mouse hippocampal neurons under different conditions and after exposure to 
fibrillar Aβ for 7 days.  Pre-incubation with MLA (10 nM) abolished Aβ-induced 
potentiation of spike activities elicited by current injection from cultured 
hippocampus pyramidal neurons, but there was no such effect upon pre-
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incubation with a selective β2-nAChR antagonist, DHβE (3 µM). B: Calculated 
number of spikes elicited by current injection from cultured hippocampal 
pyramidal neurons are lower regardless of the amount of current injected after pre-
incubation with MLA, but with DHβE. (Aβ fibril: n=8; pre-incubated with MLA: 
n = 11; t-test p < 0.01; pre-incubated with DHβE: n = 12, t-test, p > 0.05) C: 
Calculated elevation of MPs elicited by current injection from cultured 
hippocampus pyramidal neurons show that the AB-induced effect is lowered only 
after pre-incubation with MLA. (Aβ fibril: 14.82 ± 1.63 n=8; pre-incubated with 
MLA: 11.14 ± 0.98, n = 11; t-test, p < 0.01; MPs: pre-incubated with DHβE: 14.38 
± 0.86 mV, n = 12; t-test, p > 0.05).  
 
 
 
Figure 26 Pre-incubating neurons with MLA prevented chronic Aβ exposure 
induced increase of synaptic activity. 
A: Representative traces show that MLA, but not DHβE pre-incubation 
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prevented the enhancement of mEPSC in murine hippocampal pyramidal neurons 
by 100 nM Aβ fibrillar exposure for 7 days (a-c).  B: Plots of summarized data 
indicate that MLA pre-incubation prevented the enhancement of mEPSC 
frequency induced by Aβ exposure (a and b, Aβ fibril: 6.73 ± 3.58 Hz, n=8; pre-
incubated with MLA: 5.05 ± 0.33 Hz, n = 9; t-test, p < 0.01), whereas DHβE pre-
incubation failed to prevent this enhancement (a and b, pre-incubated with DHβE: 
6.40 ± 0.45 Hz, n = 8; t-test, p < 0.01).   
 
4.3.3 Inhibition or deletion of α7-nAChR prevented Aβ-induced toxicity 
To study Aβ fibril-related neuronal toxicity, we used Aβ to treat primary cultures 
of murine pyramidal neurons for different periods and detected LDH release levels 
to determine cytotoxicity of Aβ fibril treatment.  When incubated alone with 100 
nM Aβ fibrils for up to 4 days, no clear cytotoxicity was observed (Figure 27 A 
and B). However, interestingly, after 7 days of treatment, Aβ fibril displayed 
cytotoxicity, which is concurrent with the expression of neuronal hyperexcitation 
(Figure 27 A and B). Furthermore, either inhibition of α7-nAChR by pre-
incubation with MLA or deletion of α7-nAChR effectively prevented Aβ fibril 
induced neuronal cytotoxicity (Figure 27 B). These results suggest that α7-nAChR 
is a key player mediating Aβ fibril induced neuronal toxicity. 
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Figure 27 Inhibition or depletion of α7-nAChR prevented Aβ treatment 
induced neuronal toxicity. 
A: Chronic Aβ fibril-exposure induced cytotoxicity of cultured hippocampal 
pyramidal neurons is seen relative to effects of scrambled Aβ (t-test, p < 0.01). B: 
Inhibiting α7-nAChR by pre-incubation with MLA or genetic deletion of the 
receptor in α7 subunit KO mice effectively prevented Aβ fibril induced neuronal 
cytotoxicity (t-test, **p < 0.01).  
 
4.3.4 α7-/- mice exhibited low seizure susceptibility 
To test whether α7-nAChR contribute to network synchronization and seizure 
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susceptibility, we compared CCh-induced network synchronization in 
hippocampal CA1 slices from WT or α7-/- mice (6 months old) using field 
potential recordings. Figure 28 A shows that in slices from WT mice, bath-
perfusion of 50 μM CCh induced two types of network synchronization: single 
field bursting (similar to interictal) below 1 Hz, and a clustering of bursts in the 
range of 4-12 Hz (θ-oscillations, figure 29A, point by red arrows). In contrast, in 
α7-/- slices, CCh failed to induce θ-oscillations, although it still induced interictal-
like events (Figure 28 B). Since glutamatergic transmission contributes to the 
formation of these clustering bursts (Williams and Kauer, 1997), it suggests that 
α7-nAChR-mediated regulation of glutamatergic synaptic transmission may be 
important in hippocampal network synchronization. 
 
 
 
Figure 28 CCh-induced network activities in WT and α7-/- Slices.  
A: Typical traces of population discharges while 50 μM CCh was perfused 
throughout recording. In 7 slices from 3 WT mice, CCh induced both single field 
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burst and θ-oscillations. B: In 4 slices tested (from 3 α7-/- mice), CCh failed to 
induce θ-oscillations. Traces A and B were collected after perfusion of CCh for 30 
min. 
 
4.4 Discussion 
 
In these experiments, we have distinguished the roles of α7-nAChR in expression 
or induction of neuronal hyperexcitation. To evaluate roles of α7-nAChR in the 
expression of neuronal hyperexcitation, we examined the effects of a selective α7-
nAChR antagonist (MLA) on chronic Aβ exposure-induced hyperexcitation of 
cultured hippocampal neurons. MLA abolished neuronal hyperexcitation 
measured by depolarizing pulses or by rapid application of choline (selective α7-
nAChR agonist) to the recorded neuron. To examine the roles of α7-nAChR in the 
induction of neuronal hyperexcitation, α7-nAChR knockout (α7-/-) mice were 
used and compared to WT mice. Our results show that chronic Aβ exposure fails 
to induce neuronal hyperexcitation in α7-/- cultures, which suggests that α7-
nAChR play a critical role in the induction of Aβ-induced neuronal 
hyperexcitation. We also found that the cultured neurons treated with Aβ exhibit 
increased mEPSC frequency relative to those in neurons treated with scrambled 
Aβ, but that this effect is eliminated in cultured neurons prepared from α7-/- mice. 
Moreover, results from hippocampal slices show that nAChR α7-/- mice exhibit 
lower seizure susceptibility to Aβ than WT controls. Together, these findings 
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indicate a critical role played by α7-nAChR in the mediation of Aβ-induced 
neuronal hyperexcitation, and suggest that α7-nAChR is likely a specific target 
for Aβ.  
 
It has been reported that the activation of α7-nAChR plays a role in the 
modulation of neuronal excitability and synchronization. Pharmacological 
experiments demonstrate a positive correlation between the number of α-
bungarotoxin (α-BTX) binding sites in the hippocampus and sensitivity to 
nicotine-induced seizures (Miner et al., 1984, 1985; Miner and Collins, 1989). 
Damaj et al. has reported that α7-nAChR is important in mediating nicotine-
induced seizures (Damaj et al., 1999). In addition, mutant mice harboring a gain-
of-function mutation of α7-nAChR (L250T α7-nAChR) have increased sensitivity 
to both spontaneous, and nicotine-induced, seizures (Broide et al., 2002; Gil et al., 
2002). Moreover, a selective α7-nAChR partial agonist, JN403, exhibits an 
anticonvulsant property (at high doses), probably through desensitization of α7-
nAChR (Feuerbach et al., 2009). Together, these data suggest that α7-nAChR 
likely play an important role in neuronal excitation and synchronization. 
 
To distinguish the role of α7-nAChR in the expression and induction of neuronal 
hyperexcitation, in this study we discovered that chronic Aβ treatment potentiated 
membrane excitability and excitatory synaptic input to cause neuronal 
hyperexcitation and toxicity, which occurred after the up-regulation of α7-nAChR. 
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Inhibition of α7-nAChR with the selective antagonist MLA (10 nM) or depletion 
of α7-nAChR using α7-nAChR KO mice prevented both neuronal hyperexcitation 
and toxicity. These novel findings suggest that α7-nAChR play a critical role in 
the induction of Aβ-induced neuronal hyperexcitation and toxicity. Accumulating 
lines of evidence demonstrate that in AD patients and model animals, Aβ and α7-
nAChR express at an aberrantly high level, and neuronal circuits exhibit 
hyperexcitation (Hellstrom-Lindahl et al., 1999; Dineley et al., 2002b; Jones et al., 
2006; Spencer et al., 2006; Palop et al., 2007; Busche et al., 2008; Westmark et al., 
2008; Palop and Mucke, 2009a). In addition, there is evidence that α7-nAChR 
contribute to the modulation of neuronal excitability and the generation of 
epileptic seizures (Miner et al., 1986; Miner and Collins, 1989; Damaj et al., 1999; 
Ivy Carroll et al., 2007). These lines of evidence support this novel finding that 
the upregulation of α7-nAChR by Aβ may contribute to neural hyperexcitation.  
 
Our findings indicate that hyper-function of α7-nAChR induced by Aβ exposure 
contributes to AD pathology, and that attenuation of α7-nAChR function could be 
a new strategy for the treatment of AD.   
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Chapter 5 
PERSPECTIVES  
 
5.1 Conclusions 
 
 
AD patients exhibit a significantly higher incidence of unprovoked seizures 
compared to the age-matched non-AD controls, and animal models of AD display 
neural hyper-excitation and epileptic seizures (Hesdorffer et al., 1996; Mendez 
and Lim, 2003; Amatniek et al., 2006; Lozsadi and Larner, 2006; Palop et al., 
2007; Busche et al., 2008; Hommet et al., 2008; Westmark et al., 2008; Larner, 
2009; Minkeviciene et al., 2009; Palop and Mucke, 2009a). Hyperexcitation is 
particularly important because it contributes to the high incidence of epilepsy in 
AD patients (Palop and Mucke, 2009a) as well as AD-related synaptic deficits 
and neurodegeneration (Broide et al., 2002; Palop and Mucke, 2009a, b). 
Significant Aβ accumulation and deposition in AD brain is believed to be 
responsible for neural hyperexcitation. Emerging evidence indicates that α7-
nAChR is involved in AD pathology, because synaptic impairment and learning 
and memory deficits in a hAPPα7-/- mouse model are decreased by nAChR α7 
subunit gene deletion (Dziewczapolski et al., 2009). Considering that Aβ potently 
modulates α7-nAChR function (Liu et al., 2001; Pettit et al., 2001; Grassi et al., 
2003; Wu et al., 2004a; Lamb et al., 2005; Spencer et al., 2006; Liu et al., 2009), 
that α7-nAChR expression is significantly enhanced in both AD patients and 
animal models (Hellstrom-Lindahl et al., 1999; Dineley et al., 2002b; 
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Hellstrom-Lindahl et al., 2004b; Hellstrom-Lindahl et al., 2004a; Jones et al., 
2006; Counts et al., 2007; Ikonomovic et al., 2009), and that α7-nAChRs play an 
important role in regulating neuronal excitability (Dani, 2000; Sher et al., 2004; 
McKay et al., 2007), it is reasonable that α7-nAChRs may contribute to Aβ-
induced neural hyperexcitation.  
 
In this project, we hypothesized that increased α7-nAChR expression and function 
as a consequence of Aβ exposure is important in Aβ-induced neural hyper-
excitation. We found that that Aβ up-regulates α7-nAChRs, in turn inducing 
neuronal hyperexcitation. These findings explore and extend a novel relationship 
between Aβ accumulation and α7-nAChR functional dysregulation in AD 
pathogenesis. Particularly, our discovery challenges the existing concept that α7-
nAChRs are impaired in AD and that enhancing α7-nAChR function is a 
therapeutic way to treat AD.  
 
Aβ induced up-regulation of α7-nAChR expression and function and the α7-
nAChR hyperfunction contributes to neural hyperexcitation. The outcomes of our 
studies have provided new insights into the understanding of epileptogenesis and 
pathogenesis in AD. This work will also aid the selection of superior strategies for 
pharmaceutical development to prevent or attenuate Aβ-induced neuronal toxicity. 
It will not only help to explain the high incidence of epilepsy in AD, but it also 
will point to novel targets, perhaps α7-nAChR, for early therapeutic intervention.   
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